BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011;378:571-83. [PMID: 21802134 DOI: 10.1016/S0140-6736(11)61097-0] [Cited by in Crossref: 884] [Cited by in F6Publishing: 428] [Article Influence: 80.4] [Reference Citation Analysis]
Number Citing Articles
1 Zhao Y, Shi CX, McGoogan JM, Rou K, Zhang F, Wu Z. Predictors of accessing antiretroviral therapy among HIV-positive drug users in China's National Methadone Maintenance Treatment Programme. Addiction 2015;110 Suppl 1:40-50. [PMID: 25533863 DOI: 10.1111/add.12782] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
2 Hayes B, Briceno A, Asher A, Yu M, Evans JL, Hahn JA, Page K. Preference, acceptability and implications of the rapid hepatitis C screening test among high-risk young people who inject drugs. BMC Public Health 2014;14:645. [PMID: 24965699 DOI: 10.1186/1471-2458-14-645] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
3 Pericot-Valverde I, Heo M, Akiyama MJ, Norton BL, Agyemang L, Niu J, Litwin AH. Factors and HCV treatment outcomes associated with smoking among people who inject drugs on opioid agonist treatment: secondary analysis of the PREVAIL randomized clinical trial. BMC Infect Dis 2020;20:928. [PMID: 33276738 DOI: 10.1186/s12879-020-05667-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Magiorkinis G, Sypsa V, Magiorkinis E, Paraskevis D, Katsoulidou A, Belshaw R, Fraser C, Pybus OG, Hatzakis A. Integrating phylodynamics and epidemiology to estimate transmission diversity in viral epidemics. PLoS Comput Biol. 2013;9:e1002876. [PMID: 23382662 DOI: 10.1371/journal.pcbi.1002876] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 4.6] [Reference Citation Analysis]
5 Jardim ACG, Shimizu JF, Rahal P, Harris M. Plant-derived antivirals against hepatitis c virus infection. Virol J 2018;15:34. [PMID: 29439720 DOI: 10.1186/s12985-018-0945-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
6 Pracoyo NE, Suratri MA, Roselinda R, Setiawaty V. The Association of Hepatitis C Serological Status with Several Risk Factors in Indonesia. Int Sch Res Notices 2016;2016:3018135. [PMID: 27975082 DOI: 10.1155/2016/3018135] [Reference Citation Analysis]
7 Liu Y, Liu Y, Zou X, Chen W, Ling L. Trends and factors in human immunodeficiency virus and/or hepatitis C virus testing and infection among injection drug users newly entering methadone maintenance treatment in Guangdong Province, China 2006-2013: a consecutive cross sectional study. BMJ Open 2017;7:e015524. [PMID: 28710214 DOI: 10.1136/bmjopen-2016-015524] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
8 Miao Z, Gao L, Song Y, Yang M, Zhang M, Lou J, Zhao Y, Wang X, Feng Y, Dong X, Xia X. Prevalence and Clinical Impact of Human Pegivirus-1 Infection in HIV-1-Infected Individuals in Yunnan, China. Viruses 2017;9:E28. [PMID: 28212298 DOI: 10.3390/v9020028] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
9 Wiessing L, Ferri M, Běláčková V, Carrieri P, Friedman SR, Folch C, Dolan K, Galvin B, Vickerman P, Lazarus JV, Mravčík V, Kretzschmar M, Sypsa V, Sarasa-Renedo A, Uusküla A, Paraskevis D, Mendão L, Rossi D, van Gelder N, Mitcheson L, Paoli L, Gomez CD, Milhet M, Dascalu N, Knight J, Hay G, Kalamara E, Simon R, Comiskey C, Rossi C, Griffiths P; EUBEST working group. Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study. Harm Reduct J 2017;14:19. [PMID: 28431584 DOI: 10.1186/s12954-017-0141-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
10 Tao J, Liang J, Zhang H, Pei L, Qian HZ, Chambers MC, Jiang Y, Xiao Y. The Molecular Epidemiological Study of HCV Subtypes among Intravenous Drug Users and Non-Injection Drug Users in China. PLoS One 2015;10:e0140263. [PMID: 26466103 DOI: 10.1371/journal.pone.0140263] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
11 Boix R, Cano R, Gallego P, Vallejo F, Fernández-Cuenca R, Noguer I, Larrauri A. Hepatitis C hospitalizations in Spain, 2004-2013: a retrospective epidemiological study. BMC Health Serv Res 2017;17:461. [PMID: 28679375 DOI: 10.1186/s12913-017-2410-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
12 Tsui JI, Lira MC, Cheng DM, Winter MR, Alford DP, Liebschutz JM, Mao J, Edwards RR, Samet JH. Hepatitis C virus infection and pain sensitivity in patients on methadone or buprenorphine maintenance therapy for opioid use disorders. Drug Alcohol Depend 2015;153:286-92. [PMID: 26048638 DOI: 10.1016/j.drugalcdep.2015.05.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
13 Lim AG, Qureshi H, Mahmood H, Hamid S, Davies CF, Trickey A, Glass N, Saeed Q, Fraser H, Walker JG, Mukandavire C, Hickman M, Martin NK, May MT, Averhoff F, Vickerman P. Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment and prevention for achieving elimination. Int J Epidemiol 2018;47:550-60. [PMID: 29309592 DOI: 10.1093/ije/dyx270] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 11.3] [Reference Citation Analysis]
14 Chossegros P, Di Nino F. Associating conditional cash transfer to universal access to treatment could be the solution to the HCV epidemic among drug users (DUs). Harm Reduct J 2018;15:63. [PMID: 30541570 DOI: 10.1186/s12954-018-0264-4] [Reference Citation Analysis]
15 Pfaender S, Brinkmann J, Todt D, Riebesehl N, Steinmann J, Steinmann J, Pietschmann T, Steinmann E. Mechanisms of methods for hepatitis C virus inactivation. Appl Environ Microbiol 2015;81:1616-21. [PMID: 25527548 DOI: 10.1128/AEM.03580-14] [Cited by in Crossref: 33] [Cited by in F6Publishing: 16] [Article Influence: 4.1] [Reference Citation Analysis]
16 MacLachlan JH, Cowie BC. Hepatitis B virus epidemiology. Cold Spring Harb Perspect Med. 2015;5:a021410. [PMID: 25934461 DOI: 10.1101/cshperspect.a021410] [Cited by in Crossref: 114] [Cited by in F6Publishing: 98] [Article Influence: 16.3] [Reference Citation Analysis]
17 Chen L, Du L, Kang S, Ma F, Li C, He M, Bai L, Tang H. Sofosbuvir plus Ribavirin is effective for HCV elimination in people living with HIV from rural area of China. Sci Rep 2021;11:11301. [PMID: 34050222 DOI: 10.1038/s41598-021-90706-5] [Reference Citation Analysis]
18 Grebely J, Dore GJ, Morin S, Rockstroh JK, Klein MB. Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there? J Int AIDS Soc. 2017;20:22146. [PMID: 28782335 DOI: 10.7448/ias.20.1.22146] [Cited by in Crossref: 74] [Cited by in F6Publishing: 32] [Article Influence: 14.8] [Reference Citation Analysis]
19 Escobar-Gutiérrez A, Vazquez-Pichardo M, Cruz-Rivera M, Rivera-Osorio P, Carpio-Pedroza JC, Ruíz-Pacheco JA, Ruiz-Tovar K, Vaughan G. Identification of hepatitis C virus transmission using a next-generation sequencing approach. J Clin Microbiol. 2012;50:1461-1463. [PMID: 22301026 DOI: 10.1128/jcm.00005-12] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
20 McClure FL, Niles JK, Kaufman HW, Gudin J. Drug Misuse and Hepatitis C Virus Infection Profiles for Three Generations of Patients Being Monitored for Prescription Drug Adherence. J Addict Med 2019;13:123-30. [PMID: 30334927 DOI: 10.1097/ADM.0000000000000460] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Frankova S, Jandova Z, Jinochova G, Kreidlova M, Merta D, Sperl J. Therapy of chronic hepatitis C in people who inject drugs: focus on adherence. Harm Reduct J 2021;18:69. [PMID: 34193156 DOI: 10.1186/s12954-021-00519-y] [Reference Citation Analysis]
22 Karageorgopoulos DE, Allen J, Bhagani S. Hepatitis C in human immunodeficiency virus co-infected individuals: Is this still a “special population”? World J Hepatol 2015; 7(15): 1936-1952 [PMID: 26244068 DOI: 10.4254/wjh.v7.i15.1936] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
23 Cousien A, Leclerc P, Morissette C, Bruneau J, Roy É, Tran VC, Yazdanpanah Y, Cox J. The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study. BMC Infect Dis 2017;17:162. [PMID: 28222681 DOI: 10.1186/s12879-017-2256-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
24 Maurer U, Kager C, Fellinger C, Loader D, Pollesböck A, Spitzer B, Jarisch R. Risk of anaphylaxis in opioid dependent persons: effects of heroin versus substitution substance. Subst Abuse Treat Prev Policy. 2014;9:12. [PMID: 24576327 DOI: 10.1186/1747-597x-9-12] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
25 Wirtz AL, Yeh PT, Flath NL, Beyrer C, Dolan K. HIV and Viral Hepatitis Among Imprisoned Key Populations. Epidemiol Rev 2018;40:12-26. [PMID: 29688317 DOI: 10.1093/epirev/mxy003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
26 Tsui JI, Evans JL, Lum PJ, Hahn JA, Page K. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Intern Med 2014;174:1974-81. [PMID: 25347412 DOI: 10.1001/jamainternmed.2014.5416] [Cited by in Crossref: 132] [Cited by in F6Publishing: 125] [Article Influence: 18.9] [Reference Citation Analysis]
27 Strathdee SA, Arredondo J, Rocha T, Abramovitz D, Rolon ML, Patiño Mandujano E, Rangel MG, Olivarria HO, Gaines T, Patterson TL, Beletsky L. A police education programme to integrate occupational safety and HIV prevention: protocol for a modified stepped-wedge study design with parallel prospective cohorts to assess behavioural outcomes. BMJ Open 2015;5:e008958. [PMID: 26260350 DOI: 10.1136/bmjopen-2015-008958] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
28 Jordan AE, Perlman DC, Neurer J, Smith DJ, Des Jarlais DC, Hagan H. Prevalence of hepatitis C virus infection among HIV+ men who have sex with men: a systematic review and meta-analysis. Int J STD AIDS 2017;28:145-59. [PMID: 26826159 DOI: 10.1177/0956462416630910] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 6.2] [Reference Citation Analysis]
29 Jordan AE, Cleland CM, Schackman BR, Wyka K, Perlman DC, Nash D. Hepatitis C Virus (HCV) Care Continuum Outcomes and HCV Community Viral Loads Among Patients in an Opioid Treatment Program. J Infect Dis 2020;222:S335-45. [PMID: 32877560 DOI: 10.1093/infdis/jiz686] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Cezar-Vaz MR, Bonow CA, da Silva MR, de Farias FL, de Almeida MC. The Use of Illegal Drugs and Infectious Contagious Diseases: Knowledge and Intervention among Dockworkers. Int J Environ Res Public Health 2016;13:E125. [PMID: 26771625 DOI: 10.3390/ijerph13010125] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
31 Murtagh R, Swan D, O'Connor E, McCombe G, Lambert JS, Avramovic G, Cullen W. Hepatitis C Prevalence and Management Among Patients Receiving Opioid Substitution Treatment in General Practice in Ireland: Baseline Data from a Feasibility Study. Interact J Med Res 2018;7:e10313. [PMID: 30567692 DOI: 10.2196/10313] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
32 Aspinall EJ, Doyle JS, Corson S, Hellard ME, Hunt D, Goldberg D, Nguyen T, Falck-Ytter Y, Morgan RL, Smith B, Stoove M, Wiktor SZ, Hutchinson S. Targeted hepatitis C antibody testing interventions: a systematic review and meta-analysis. Eur J Epidemiol 2015;30:115-29. [PMID: 25385677 DOI: 10.1007/s10654-014-9958-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
33 Yen YF, Yen MY, Su LW, Li LH, Chuang P, Jiang XR, Deng CY. Prevalences and associated risk factors of HCV/HIV co-infection and HCV mono-infection among injecting drug users in a methadone maintenance treatment program in Taipei, Taiwan. BMC Public Health 2012;12:1066. [PMID: 23227904 DOI: 10.1186/1471-2458-12-1066] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
34 Bailey H, Nizova N, Martsynovska V, Volokha A, Malyuta R, Cortina-Borja M, Thorne C; Ukraine European Collaborative Study in EuroCoord. HCV co-infection and markers of liver injury and fibrosis among HIV-positive childbearing women in Ukraine: results from a cohort study. BMC Infect Dis 2016;16:755. [PMID: 27955711 DOI: 10.1186/s12879-016-2089-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
35 Auriacombe M, Roux P, Briand Madrid L, Kirchherr S, Kervran C, Chauvin C, Gutowski M, Denis C, Carrieri MP, Lalanne L, Jauffret-Roustide M; Cosinus study group. Impact of drug consumption rooms on risk practices and access to care in people who inject drugs in France: the COSINUS prospective cohort study protocol. BMJ Open 2019;9:e023683. [PMID: 30796121 DOI: 10.1136/bmjopen-2018-023683] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
36 Schìtz A, Moser S, Marchart K, Haltmayer H, Gschwantler M. Direct Observed Therapy of Chronic Hepatitis C With Interferon-Free All-Oral Regimens at a Low-Threshold Drug Treatment Facility-a New Concept for Treatment of Patients With Borderline Compliance Receiving Opioid Substitution Therapy. Am J Gastroenterol 2016;111:903-5. [PMID: 27249993 DOI: 10.1038/ajg.2016.119] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
37 Falade-Nwulia O, Gicquelais RE, Astemborski J, McCormick SD, Kirk G, Sulkowski M, Thomas DL, Mehta SH. Hepatitis C treatment uptake among people who inject drugs in the oral direct-acting antiviral era. Liver Int 2020;40:2407-16. [PMID: 32770638 DOI: 10.1111/liv.14634] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
38 Bluthenthal RN, Wenger L, Chu D, Bourgois P, Kral AH. Drug use generations and patterns of injection drug use: Birth cohort differences among people who inject drugs in Los Angeles and San Francisco, California. Drug Alcohol Depend 2017;175:210-8. [PMID: 28448905 DOI: 10.1016/j.drugalcdep.2017.04.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
39 Rao H, Wei L, Lopez-Talavera JC, Shang J, Chen H, Li J, Xie Q, Gao Z, Wang L, Wei J, Jiang J, Sun Y, Yang R, Li H, Zhang H, Gong Z, Zhang L, Zhao L, Dou X, Niu J, You H, Chen Z, Ning Q, Gong G, Wu S, Ji W, Mao Q, Tang H, Li S, Wei S, Sun J, Jiang J, Lu L, Jia J, Zhuang H. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2014;29:545-553. [PMID: 24090188 DOI: 10.1111/jgh.12398] [Cited by in Crossref: 87] [Cited by in F6Publishing: 86] [Article Influence: 10.9] [Reference Citation Analysis]
40 Tsui JI, Barry MP, Austin EJ, Sweek EW, Tung E, Hansen RN, Ninburg M, Scott JD, Glick SN, Williams EC. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs. Addict Sci Clin Pract 2021;16:52. [PMID: 34384494 DOI: 10.1186/s13722-021-00260-8] [Reference Citation Analysis]
41 Werb D, Garfein R, Kerr T, Davidson P, Roux P, Jauffret-Roustide M, Auriacombe M, Small W, Strathdee SA. A socio-structural approach to preventing injection drug use initiation: rationale for the PRIMER study. Harm Reduct J 2016;13:25. [PMID: 27629248 DOI: 10.1186/s12954-016-0114-1] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 6.5] [Reference Citation Analysis]
42 Rose R, Rodriguez C, Dollar JJ, Lamers SL, Massaccesi G, Osburn W, Ray SC, Thomas DL, Cox AL, Laeyendecker O. Inconsistent temporal patterns of genetic variation of HCV among high-risk subjects may impact inference of transmission networks. Infect Genet Evol 2019;71:1-6. [PMID: 30802530 DOI: 10.1016/j.meegid.2019.02.025] [Reference Citation Analysis]
43 Armstrong G, Nuken A, Medhi GK, Mahanta J, Humtsoe C, Lalmuanpuaii M, Kermode M. Injecting drug use in Manipur and Nagaland, Northeast India: injecting and sexual risk behaviours across age groups. Harm Reduct J 2014;11:27. [PMID: 25312004 DOI: 10.1186/1477-7517-11-27] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
44 Schramm ZA, Leroux BG, Radick AC, Ventura AS, Klein JW, Samet JH, Saxon AJ, Kim TW, Tsui JI. Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment: protocol for a pilot randomized controlled trial. Addict Sci Clin Pract 2020;15:30. [PMID: 32736660 DOI: 10.1186/s13722-020-00203-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
45 Bertin C, Delorme J, Riquelme M, Peyrière H, Brousse G, Eschalier A, Ardid D, Chenaf C, Authier N. Risk assessment of using off-label morphine sulfate in a population-based retrospective cohort of opioid-dependent patients. Br J Clin Pharmacol 2020;86:2338-48. [PMID: 31389036 DOI: 10.1111/bcp.14082] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
46 Owiti JA, Greenhalgh T, Sweeney L, Foster GR, Bhui KS. Illness perceptions and explanatory models of viral hepatitis B & C among immigrants and refugees: a narrative systematic review. BMC Public Health 2015;15:151. [PMID: 25886390 DOI: 10.1186/s12889-015-1476-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
47 Honarvar B, Odoomi N, Moghadami M, Afsar Kazerooni P, Hassanabadi A, Zare Dolatabadi P, Farzanfar E, Lankarani KB. Blood-borne hepatitis in opiate users in iran: a poor outlook and urgent need to change nationwide screening policy. PLoS One 2013;8:e82230. [PMID: 24312645 DOI: 10.1371/journal.pone.0082230] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
48 Koustenis KR, Anagnostou O, Kranidioti H, Vasileiadi S, Antonakaki P, Koutli E, Pantsas P, Deutsch M, Manolakopoulos S. Direct-acting antiviral treatment for chronic hepatitis C in people who use drugs in a real-world setting. Ann Gastroenterol. 2020;33:195-201. [PMID: 32127741 DOI: 10.20524/aog.2020.0449] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Smith DJ, Combellick J, Jordan AE, Hagan H. Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis. Int J Drug Policy. 2015;26:911-921. [PMID: 26298331 DOI: 10.1016/j.drugpo.2015.07.004] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 8.7] [Reference Citation Analysis]
50 Armenta RF, Roth AM, Wagner KD, Strathdee SA, Brodine SK, Cuevas-Mota J, Munoz FA, Garfein RS. Prevalence and Correlates of the Use of Prefilled Syringes Among Persons Who Inject Drugs in San Diego, CA. J Urban Health 2015;92:1081-91. [PMID: 26382653 DOI: 10.1007/s11524-015-9988-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
51 Schulte M, Hser Y, Saxon A, Evans E, Li L, Huang D, Hillhouse M, Thomas C, Ling W. Risk Factors Associated with HCV Among Opioid-Dependent Patients in a Multisite Study. J Community Health 2015;40:940-7. [PMID: 25814381 DOI: 10.1007/s10900-015-0016-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
52 Grebely J, Bruneau J, Lazarus JV, Dalgard O, Bruggmann P, Treloar C, Hickman M, Hellard M, Roberts T, Crooks L. Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. Int J Drug Policy. 2017;47:51-60. [PMID: 28683982 DOI: 10.1016/j.drugpo.2017.05.019] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 8.4] [Reference Citation Analysis]
53 Stephens DB, Young AM, Havens JR. Healthcare contact and treatment uptake following hepatitis C virus screening and counseling among rural Appalachian people who use drugs. Int J Drug Policy 2017;47:86-94. [PMID: 28648353 DOI: 10.1016/j.drugpo.2017.05.045] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
54 Riondel A, Huong DT, Michel L, Peries M, Oanh KTH, Khue PM, Thanh NTT, Giang HT, Vallo R, Cournil A, Rapoud D, Quillet C, Laureillard D, Vinh VH, Moles JP, Feelemyer J, Hammett T, Jarlais DD, Nagot N. Towards Targeted Interventions in Low- and Middle-Income Countries: Risk Profiles of People Who Inject Drugs in Haiphong (Vietnam). Biomed Res Int 2020;2020:8037193. [PMID: 32964044 DOI: 10.1155/2020/8037193] [Reference Citation Analysis]
55 Alonso M, Gutzman A, Mazin R, Pinzon CE, Reveiz L, Ghidinelli M. Hepatitis C in key populations in Latin America and the Caribbean: systematic review and meta-analysis. Int J Public Health 2015;60:789-98. [PMID: 26298439 DOI: 10.1007/s00038-015-0708-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
56 Swart A, Burns L, Mao L, Grulich AE, Amin J, O’Connell DL, Meagher NS, Randall DA, Degenhardt L, Vajdic CM. The importance of blood-borne viruses in elevated cancer risk among opioid-dependent people: a population-based cohort study. BMJ Open. 2012;2:e001755. [PMID: 23045358 DOI: 10.1136/bmjopen-2012-001755] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
57 Alghamdi AS, Alghamdi M, Sanai FM, Alghamdi H, Aba-Alkhail F, Alswat K, Babatin M, Alqutub A, Altraif I, Alfaleh F. SASLT guidelines: Update in treatment of Hepatitis C virus infection. Saudi J Gastroenterol 2016;22 Suppl:S25-57. [PMID: 27538727 DOI: 10.4103/1319-3767.188067] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
58 Nic An Riogh E, Swan D, McCombe G, O'Connor E, Avramovic G, Macías J, Oprea C, Story A, Surey J, Vickerman P, Ward Z, Lambert JS, Tinago W, Ianache I, Iglesias M, Cullen W. Integrating hepatitis C care for at-risk groups (HepLink): baseline data from a multicentre feasibility study in primary and community care. J Antimicrob Chemother 2019;74:v31-8. [PMID: 31782502 DOI: 10.1093/jac/dkz454] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
59 Sacks-Davis R, Aitken CK, Higgs P, Spelman T, Pedrana AE, Bowden S, Bharadwaj M, Nivarthi UK, Suppiah V, George J, Grebely J, Drummer HE, Hellard M. High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study. PLoS One 2013;8:e80216. [PMID: 24244654 DOI: 10.1371/journal.pone.0080216] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 5.0] [Reference Citation Analysis]
60 Elsherif O, Bannan C, Keating S, McKiernan S, Bergin C, Norris S. Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response. PLoS One 2017;12:e0178398. [PMID: 28636638 DOI: 10.1371/journal.pone.0178398] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
61 Hochstatter KR, Gustafson DH Sr, Landucci G, Pe-Romashko K, Maus A, Shah DV, Taylor QA, Gill EK, Miller R, Krechel S, Westergaard RP. A Mobile Health Intervention to Improve Hepatitis C Outcomes Among People With Opioid Use Disorder: Protocol for a Randomized Controlled Trial. JMIR Res Protoc 2019;8:e12620. [PMID: 31373273 DOI: 10.2196/12620] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
62 Mansberg K, Kull K, Salupere R, Prükk T, Margus B, Kariis T, Remmel T, Suurmaa K, Ott K, Jaago K, Šmidt J. A Population-Based Surveillance Study on the Epidemiology of Hepatitis C in Estonia. Medicina (Kaunas) 2018;54:E9. [PMID: 30344240 DOI: 10.3390/medicina54010009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
63 Jordan AE, Des Jarlais DC, Arasteh K, McKnight C, Nash D, Perlman DC. Incidence and prevalence of hepatitis c virus infection among persons who inject drugs in New York City: 2006-2013. Drug Alcohol Depend 2015;152:194-200. [PMID: 25891230 DOI: 10.1016/j.drugalcdep.2015.03.039] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 5.1] [Reference Citation Analysis]
64 Falade-Nwulia O, Momoh O, Felsher M, Nwulia E, Tofighi B, Ward K, McCormick S, Sulkowski M, Latkin C. Validation of a tool to assess effectiveness of peer-recruitment for hepatitis C testing and linkage to care among people who inject drugs. Drug Alcohol Depend 2022;230:109177. [PMID: 34808487 DOI: 10.1016/j.drugalcdep.2021.109177] [Reference Citation Analysis]
65 Yi S, Mun P, Chhoun P, Chann N, Tuot S, Mburu G. Prevalence of and risk factors for hepatitis C virus antibody among people who inject drugs in Cambodia: a national biological and behavioral survey. Harm Reduct J 2019;16:29. [PMID: 31036011 DOI: 10.1186/s12954-019-0299-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
66 Taylor LE. Colocalization in Hepatitis C Virus Infection Care: The Role of Opioid Agonist Therapy Clinics. Clin Liver Dis (Hoboken) 2020;16:12-5. [PMID: 32714517 DOI: 10.1002/cld.921] [Reference Citation Analysis]
67 Hellard M, Doyle JS, Sacks-Davis R, Thompson AJ, McBryde E. Eradication of hepatitis C infection: the importance of targeting people who inject drugs. Hepatology 2014;59:366-9. [PMID: 23873507 DOI: 10.1002/hep.26623] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 7.6] [Reference Citation Analysis]
68 Zou X, Ling L, Zhang L. Trends and risk factors for HIV, HCV and syphilis seroconversion among drug users in a methadone maintenance treatment programme in China: a 7-year retrospective cohort study. BMJ Open 2015;5:e008162. [PMID: 26297365 DOI: 10.1136/bmjopen-2015-008162] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
69 Litwin AH, Shafner L, Norton B, Akiyama MJ, Agyemang L, Guzman M, Vera T, Heo M. Artificial Intelligence Platform Demonstrates High Adherence in Patients Receiving Fixed-Dose Ledipasvir and Sofosbuvir: A Pilot Study. Open Forum Infect Dis 2020;7:ofaa290. [PMID: 32818140 DOI: 10.1093/ofid/ofaa290] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
70 Davis SM, Daily S, Kristjansson AL, Kelley GA, Zullig K, Baus A, Davidov D, Fisher M. Needle exchange programs for the prevention of hepatitis C virus infection in people who inject drugs: a systematic review with meta-analysis. Harm Reduct J. 2017;14:25. [PMID: 28514954 DOI: 10.1186/s12954-017-0156-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
71 Iversen J, Wand H, Topp L, Kaldor J, Maher L. Reduction in HCV incidence among injection drug users attending needle and syringe programs in Australia: a linkage study. Am J Public Health 2013;103:1436-44. [PMID: 23763399 DOI: 10.2105/AJPH.2012.301206] [Cited by in Crossref: 43] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
72 Cunningham EB, Hajarizadeh B, Dalgard O, Amin J, Hellard M, Foster GR, Bruggmann P, Conway B, Backmund M, Robaeys G, Swan T, Marks PS, Quiene S, Applegate TL, Weltman M, Shaw D, Dunlop A, Bruneau J, Midgard H, Bourgeois S, Thurnheer MC, Dore GJ, Grebely J; ACTIVATE Study Group. Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. BMC Infect Dis 2017;17:420. [PMID: 28610605 DOI: 10.1186/s12879-017-2517-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
73 Mravčík V, Strada L, Stolfa J, Bencko V, Groshkova T, Reimer J, Schulte B. Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review. Patient Prefer Adherence 2013;7:1067-75. [PMID: 24204126 DOI: 10.2147/PPA.S49113] [Cited by in Crossref: 42] [Cited by in F6Publishing: 23] [Article Influence: 4.7] [Reference Citation Analysis]
74 Scott N, Win TM, Tidhar T, Htay H, Draper B, Aung PTZ, Xiao Y, Bowring A, Kuschel C, Shilton S, Kyi KP, Naing W, Aung KS, Hellard M. Hepatitis C elimination in Myanmar: Modelling the impact, cost, cost-effectiveness and economic benefits. Lancet Reg Health West Pac 2021;10:100129. [PMID: 34327345 DOI: 10.1016/j.lanwpc.2021.100129] [Reference Citation Analysis]
75 Fu R, Gutfraind A, Brandeau ML. Modeling a dynamic bi-layer contact network of injection drug users and the spread of blood-borne infections. Math Biosci 2016;273:102-13. [PMID: 26775738 DOI: 10.1016/j.mbs.2016.01.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
76 Roux P, Rojas Castro D, Ndiaye K, Debrus M, Protopopescu C, Le Gall JM, Haas A, Mora M, Spire B, Suzan-Monti M, Carrieri P. Increased Uptake of HCV Testing through a Community-Based Educational Intervention in Difficult-to-Reach People Who Inject Drugs: Results from the ANRS-AERLI Study. PLoS One 2016;11:e0157062. [PMID: 27294271 DOI: 10.1371/journal.pone.0157062] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
77 Hashemi Shahri SM, Ansari-moghadam F, Ansari Moghadam A. A Survey on HIV, HCV, and HBV and Related Factors Among the Homeless Population, Southeast of Iran. Health Scope 2021;10. [DOI: 10.5812/jhealthscope.108929] [Reference Citation Analysis]
78 Villar LM, Amado LA, de Almeida AJ, de Paula VS, Lewis-Ximenez LL, Lampe E. Low prevalence of hepatitis B and C virus markers among children and adolescents. Biomed Res Int. 2014;2014:324638. [PMID: 25093164 DOI: 10.1155/2014/324638] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
79 Stone J, Martin NK, Hickman M, Hellard M, Scott N, McBryde E, Drummer H, Vickerman P. The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals? PLoS One 2016;11:e0156213. [PMID: 27224423 DOI: 10.1371/journal.pone.0156213] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
80 Toro-Tobón D, Berbesi-Fernandez D, Mateu-Gelabert P, Segura-Cardona ÁM, Montoya-Vélez LP. Prevalence of hepatitis C virus in young people who inject drugs in four Colombian cities: A cross-sectional study using Respondent Driven Sampling. Int J Drug Policy 2018;60:56-64. [PMID: 30107313 DOI: 10.1016/j.drugpo.2018.07.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
81 Zheng Y, Obeng S, Wang H, Jali AM, Peddibhotla B, Williams DA, Zou C, Stevens DL, Dewey WL, Akbarali HI, Selley DE, Zhang Y. Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives as μ/κ Opioid Receptor Dual Selective Ligands. J Med Chem 2019;62:561-74. [PMID: 30608693 DOI: 10.1021/acs.jmedchem.8b01158] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
82 Lima VD, Rozada I, Grebely J, Hull M, Lourenco L, Nosyk B, Krajden M, Yoshida E, Wood E, Montaner JS. Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs? PLoS One 2015;10:e0143836. [PMID: 26633652 DOI: 10.1371/journal.pone.0143836] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
83 Lemoine M, Nayagam S, Thursz M. Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges. Future Virol. 2013;8:371-380. [PMID: 23662157 DOI: 10.2217/fvl.13.11] [Cited by in Crossref: 77] [Cited by in F6Publishing: 64] [Article Influence: 8.6] [Reference Citation Analysis]
84 Uojima H, Murakami S, Nakatani S, Hidaka H, Takeuchi A, Tanaka Y, Inoue T, Yamane K, Kubota K, Nakazawa T, Shibuya A, Tanaka Y, Koizumi W. Late Relapse after a Sustained Virologic Response at 24 Weeks after Treatment with Daclatasvir and Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b Infection with Liver Cirrhosis. Intern Med 2018;57:951-6. [PMID: 29225269 DOI: 10.2169/internalmedicine.9671-17] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
85 Dulskas A, Kavaliauskas P, Zagminas K, Jancoriene L, Smailyte G. Trends in Incidence and Mortality of Primary Liver Cancer in Lithuania 1998-2015. Int J Environ Res Public Health 2021;18:1191. [PMID: 33572744 DOI: 10.3390/ijerph18031191] [Reference Citation Analysis]
86 Andreoni M, Coppola N, Craxì A, Fagiuoli S, Gardini I, Mangia A, Nava FA, Pasqualetti P. Meet-Test-Treat for HCV management: patients' and clinicians' preferences in hospital and drug addiction services in Italy. BMC Infect Dis 2022;22:3. [PMID: 34983405 DOI: 10.1186/s12879-021-06983-y] [Reference Citation Analysis]
87 Lambdin BH, Lorvick J, Mbwambo JK, Rwegasha J, Hassan S, Lum P, Kral AH. Prevalence and predictors of HCV among a cohort of opioid treatment patients in Dar es Salaam, Tanzania. Int J Drug Policy 2017;45:64-9. [PMID: 28628854 DOI: 10.1016/j.drugpo.2017.05.043] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
88 Gispen MEC. A human rights view on access to controlled substances for medical purposes under the international drug control framework. Eur J Pharmacol 2013;719:16-24. [PMID: 23872413 DOI: 10.1016/j.ejphar.2013.04.062] [Reference Citation Analysis]
89 Choo MK, El-Bassel N, Adam PC, Gilbert L, Wu E, West BS, Bazazi AR, De Wit JB, Ismail R, Kamarulzaman A. Prevalence and Correlates of HIV and Hepatitis C Virus Infections and Risk Behaviors among Malaysian Fishermen. PLoS One 2015;10:e0118422. [PMID: 26244844 DOI: 10.1371/journal.pone.0118422] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
90 Ahmed B, Ali T, Qureshi H, Hamid S. Population-attributable estimates for risk factors associated with hepatitis B and C: policy implications for Pakistan and other South Asian countries. Hepatol Int 2013;7:500-7. [PMID: 26201782 DOI: 10.1007/s12072-012-9417-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
91 Saeed S, Strumpf EC, Moodie EE, Young J, Nitulescu R, Cox J, Wong A, Walmsely S, Cooper C, Vachon ML, Martel-Laferriere V, Hull M, Conway B, Klein MB; Canadian Co-Infection Cohort Study. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada. J Int AIDS Soc 2017;20. [PMID: 29116684 DOI: 10.1002/jia2.25013] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
92 Crowley D, Van Hout MC, Lambert JS, Kelly E, Murphy C, Cullen W. Barriers and facilitators to hepatitis C (HCV) screening and treatment-a description of prisoners' perspective. Harm Reduct J. 2018;15:62. [PMID: 30538000 DOI: 10.1186/s12954-018-0269-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
93 Platt L, French CE, McGowan CR, Sabin K, Gower E, Trickey A, McDonald B, Ong J, Stone J, Easterbrook P, Vickerman P. Prevalence and burden of HBV co-infection among people living with HIV: A global systematic review and meta-analysis. J Viral Hepat. 2020;27:294-315. [PMID: 31603999 DOI: 10.1111/jvh.13217] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
94 Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen KJ, Hatzakis A, Prins M, Vickerman P, Lazarus JV. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One. 2014;9:e103345. [PMID: 25068274 DOI: 10.1371/journal.pone.0103345] [Cited by in Crossref: 151] [Cited by in F6Publishing: 142] [Article Influence: 18.9] [Reference Citation Analysis]
95 Falla AM, Hofstraat SHI, Duffell E, Hahné SJM, Tavoschi L, Veldhuijzen IK. Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups. BMC Infect Dis 2018;18:79. [PMID: 29433454 DOI: 10.1186/s12879-018-2988-x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 11.8] [Reference Citation Analysis]
96 Phelan M, Cook C. A treatment revolution for those who can afford it? Hepatitis C treatment: new medications, profits and patients. BMC Infect Dis. 2014;14 Suppl 6:S5. [PMID: 25253373 DOI: 10.1186/1471-2334-14-s6-s5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
97 Kawambwa RH, Majigo MV, Mohamed AA, Matee MI. High prevalence of human immunodeficiency virus, hepatitis B and C viral infections among people who inject drugs: a potential stumbling block in the control of HIV and viral hepatitis in Tanzania. BMC Public Health 2020;20:177. [PMID: 32019536 DOI: 10.1186/s12889-020-8294-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
98 Huy BV, Vernavong K, Kính NV. HBV and HCV Coinfection among HIV/AIDS Patients in the National Hospital of Tropical Diseases, Vietnam. AIDS Res Treat 2014;2014:581021. [PMID: 25580287 DOI: 10.1155/2014/581021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
99 Gaska JM, Ding Q, Ploss A. Mouse Models for Studying HCV Vaccines and Therapeutic Antibodies. Methods Mol Biol 2019;1911:481-503. [PMID: 30593647 DOI: 10.1007/978-1-4939-8976-8_33] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
100 Khan B, Duncan I, Saad M, Schaefer D, Jordan A, Smith D, Neaigus A, Des Jarlais D, Hagan H, Dombrowski K. Combination interventions for Hepatitis C and Cirrhosis reduction among people who inject drugs: An agent-based, networked population simulation experiment. PLoS One 2018;13:e0206356. [PMID: 30496209 DOI: 10.1371/journal.pone.0206356] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
101 Quinn K, Fong C, Guarino H, Mateu-Gelabert P. Development, validation, and potential applications of the hepatitis C virus injection-risk knowledge scale (HCV-IRKS) among young opioid users in New York City. Drug Alcohol Depend 2019;194:453-9. [PMID: 30503906 DOI: 10.1016/j.drugalcdep.2018.11.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
102 Herrmann ES, Matusiewicz AK, Stitzer ML, Higgins ST, Sigmon SC, Heil SH. Contingency Management Interventions for HIV, Tuberculosis, and Hepatitis Control Among Individuals With Substance Use Disorders: A Systematized Review. J Subst Abuse Treat 2017;72:117-25. [PMID: 27394070 DOI: 10.1016/j.jsat.2016.06.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
103 Chahal HS, Peters MG, Harris AM, McCabe D, Volberding P, Kahn JG. Cost-effectiveness of Hepatitis B Virus Infection Screening and Treatment or Vaccination in 6 High-risk Populations in the United States. Open Forum Infect Dis 2019;6:ofy353. [PMID: 30931346 DOI: 10.1093/ofid/ofy353] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
104 Minosse C, Gruber CEM, Rueca M, Taibi C, Zaccarelli M, Grilli E, Montalbano M, Capobianchi MR, Antinori A, D'Offizi G, McPhee F, Garbuglia AR. Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs. Viruses 2021;13:1151. [PMID: 34208646 DOI: 10.3390/v13061151] [Reference Citation Analysis]
105 Hainsworth SW, Dietze PM, Wilson DP, Sutton B, Hellard ME, Scott N. Hepatitis C virus notification rates in Australia are highest in socioeconomically disadvantaged areas. PLoS One 2018;13:e0198336. [PMID: 29912897 DOI: 10.1371/journal.pone.0198336] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
106 Taleban R, Moafi M, Ataei B, Yaran M, Nokhodian Z, Kassaian N, Adibi P, Javadi A. Seroprevalence of Hepatitis B Infection and Associated Risk Factors among Drug Users in Drop-in Centers of Isfahan, Iran. Int J Prev Med 2018;9:46. [PMID: 29899884 DOI: 10.4103/ijpvm.IJPVM_382_16] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
107 Li M, Li R, Shen Z, Li C, Liang N, Peng Z, Huang W, He C, Zhong F, Tang X, Lan G. Spatial distribution of HIV, HCV, and co-infections among drug users in the southwestern border areas of China (2004-2014): a cohort study of a national methadone maintenance treatment program. BMC Public Health 2017;17:759. [PMID: 28962612 DOI: 10.1186/s12889-017-4769-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
108 Fu X, Chen K, Liao X, Shen K. Case report: surgical removal of a migrated needle in right ventricle of an intravenous drug user. Subst Abuse Treat Prev Policy 2017;12:51. [PMID: 29216882 DOI: 10.1186/s13011-017-0134-1] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
109 Gountas I, Sypsa V, Blach S, Razavi H, Hatzakis A. HCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era. PLoS One. 2018;13:e0202109. [PMID: 30114207 DOI: 10.1371/journal.pone.0202109] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
110 Alavi M, Spelman T, Matthews GV, Haber PS, Day C, van Beek I, Walsh N, Yeung B, Bruneau J, Petoumenos K, Dolan K, Kaldor JM, Dore GJ, Hellard M, Grebely J; ATAHC Study Group. Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. Int J Drug Policy 2015;26:976-83. [PMID: 26115881 DOI: 10.1016/j.drugpo.2015.05.003] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
111 Jacka B, Bray BC, Applegate TL, Marshall BDL, Lima VD, Hayashi K, DeBeck K, Raghwani J, Harrigan PR, Krajden M, Montaner JSG, Grebely J Senior. Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach. J Viral Hepat 2018;25:28-36. [PMID: 28719060 DOI: 10.1111/jvh.12758] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
112 Akyar E, Seneca KH, Akyar S, Schofield N, Schwartz MP, Nahass RG. Linkage to Care for Suburban Heroin Users with Hepatitis C Virus Infection, New Jersey, USA. Emerg Infect Dis 2016;22:907-9. [PMID: 27089172 DOI: 10.3201/eid2205.151980] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
113 Zhang JY, Li ZB, Zhang L, Wang J, Huang LP, Zhan GL, Li Z, Du J, Zhao M. DOES IT WORK? -a randomized controlled trial to test the efficacy of HCV and HIV-related education on drug users in MMT, China. BMC Infect Dis 2019;19:774. [PMID: 31488064 DOI: 10.1186/s12879-019-4421-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
114 Prevost TC, Presanis AM, Taylor A, Goldberg DJ, Hutchinson SJ, De Angelis D. Estimating the number of people with hepatitis C virus who have ever injected drugs and have yet to be diagnosed: an evidence synthesis approach for Scotland. Addiction 2015;110:1287-300. [PMID: 25876667 DOI: 10.1111/add.12948] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
115 Durier N, Nguyen C, White LJ. Treatment of hepatitis C as prevention: a modeling case study in Vietnam. PLoS One 2012;7:e34548. [PMID: 22511949 DOI: 10.1371/journal.pone.0034548] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
116 Sardashti S, Samaei M, Firouzeh MM, Mirshahvalad SA, Pahlaviani FG, SeyedAlinaghi S. Early initiation of antiretroviral treatment: Challenges in the Middle East and North Africa. World J Virology 2015; 4(2): 134-141 [PMID: 25964878 DOI: 10.5501/wjv.v4.i2.134] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
117 Coller KE, Berg MG, Frankel M, Forberg K, Surani R, Chiu CY, Hackett J Jr, Dawson GJ. Antibodies to the Novel Human Pegivirus 2 Are Associated with Active and Resolved Infections. J Clin Microbiol 2016;54:2023-30. [PMID: 27225404 DOI: 10.1128/JCM.00515-16] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
118 Piao HX, Yang AT, Sun YM, Kong YY, Wu XN, Zhang YZ, Ding B, Wang BE, Jia JD, You H. Increasing newly diagnosed rate and changing risk factors of HCV in Yanbian Prefecture, a high endemic area in China. PLoS One 2014;9:e86190. [PMID: 24475084 DOI: 10.1371/journal.pone.0086190] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
119 Chemaitelly H, Chaabna K, Abu-Raddad LJ. The Epidemiology of Hepatitis C Virus in the Fertile Crescent: Systematic Review and Meta-Analysis. PLoS One. 2015;10:e0135281. [PMID: 26296200 DOI: 10.1371/journal.pone.0135281] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 5.9] [Reference Citation Analysis]
120 Zhang L, Celentano DD, Le Minh N, Latkin CA, Mehta SH, Frangakis C, Ha TV, Mo TT, Sripaipan T, Davis WW. Prevalence and correlates of HCV monoinfection and HIV and HCV coinfection among persons who inject drugs in Vietnam. Eur J Gastroenterol Hepatol. 2015;27:550-556. [PMID: 25769097 DOI: 10.1097/meg.0000000000000321] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
121 Le Ngoc C, Tran Thi Thanh T, Tran Thi Lan P, Nguyen Mai T, Nguyen Hoa T, Nghiem My N, Le Van T, Le Manh H, Le Thanh P, Nguyen Van Vinh C, Thwaites G, Cooke G, Heilek GM, Shikuma C, Le T, Baker S, Rahman M; VIZIONS consortium. Differential prevalence and geographic distribution of hepatitis C virus genotypes in acute and chronic hepatitis C patients in Vietnam. PLoS One 2019;14:e0212734. [PMID: 30865664 DOI: 10.1371/journal.pone.0212734] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
122 Arain A, Robaeys G. Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. World J Gastroenterol 2014; 20(36): 12722-12733 [PMID: 25278674 DOI: 10.3748/wjg.v20.i36.12722] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
123 Martin NK, Hickman M, Miners A, Hutchinson SJ, Taylor A, Vickerman P. Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. BMJ Open. 2013;3. [PMID: 23943776 DOI: 10.1136/bmjopen-2013-003153] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 6.7] [Reference Citation Analysis]
124 Hser YI, Liang D, Lan YC, Vicknasingam BK, Chakrabarti A. Drug Abuse, HIV, and HCV in Asian Countries. J Neuroimmune Pharmacol 2016;11:383-93. [PMID: 27000123 DOI: 10.1007/s11481-016-9665-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
125 Maticic M, Zorman JV, Gregorcic S, Schatz E, Lazarus JV. Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: a cross-sectional survey of 34 European countries. Harm Reduct J 2019;16:32. [PMID: 31072401 DOI: 10.1186/s12954-019-0303-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
126 Harvey L, Taylor JL, Assoumou SA, Kehoe J, Schechter-Perkins EM, Bernstein E, Walley AY. Sexually Transmitted and Blood-borne Infections Among Patients Presenting to a Low-barrier Substance Use Disorder Medication Clinic. J Addict Med 2021;15:461-7. [PMID: 34734572 DOI: 10.1097/ADM.0000000000000801] [Reference Citation Analysis]
127 Zhou K, Hu F, Wang C, Xu M, Lan Y, Morano JP, Lemon SM, Tucker JD, Cai W. Genotypic distribution and hepatic fibrosis among HIV/HCV co-infected individuals in Southern China: a retrospective cross-sectional study. BMC Infect Dis 2015;15:401. [PMID: 26424404 DOI: 10.1186/s12879-015-1135-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
128 Landry M, Veilleux N, Arseneault JE, Abboud S, Barrieau A, Bélanger M. Impact of a methadone maintenance program on an Aboriginal community: a qualitative study. CMAJ Open 2016;4:E431-5. [PMID: 27730106 DOI: 10.9778/cmajo.20150076] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
129 Dombrowski K, Khan B, Habecker P, Hagan H, Friedman SR, Saad M. The Interaction of Risk Network Structures and Virus Natural History in the Non-spreading of HIV Among People Who Inject Drugs in the Early Stages of the Epidemic. AIDS Behav 2017;21:1004-15. [PMID: 27699596 DOI: 10.1007/s10461-016-1568-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
130 Habecker P, Abadie R, Welch-Lazoritz M, Reyes JC, Khan B, Dombrowski K. Injection Partners, HCV, and HIV Status among Rural Persons Who Inject Drugs in Puerto Rico. Subst Use Misuse 2018;53:1128-38. [PMID: 29166134 DOI: 10.1080/10826084.2017.1400562] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
131 Clémençon S, Cousien A, Felipe MD, Tran VC. On computer-intensive simulation and estimation methods for rare-event analysis in epidemic models. Stat Med 2015;34:3696-713. [PMID: 26242476 DOI: 10.1002/sim.6596] [Reference Citation Analysis]
132 Markov PV, van de Laar TJ, Thomas XV, Aronson SJ, Weegink CJ, van den Berk GE, Prins M, Pybus OG, Schinkel J. Colonial history and contemporary transmission shape the genetic diversity of hepatitis C virus genotype 2 in Amsterdam. J Virol 2012;86:7677-87. [PMID: 22573865 DOI: 10.1128/JVI.06910-11] [Cited by in Crossref: 42] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
133 Ross RS, Stambouli O, Grüner N, Marcus U, Cai W, Zhang W, Zimmermann R, Roggendorf M. Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots--performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification. Virol J. 2013;10:72. [PMID: 23497102 DOI: 10.1016/j.antiviral.2011.12.011] [Cited by in Crossref: 92] [Cited by in F6Publishing: 80] [Article Influence: 10.2] [Reference Citation Analysis]
134 Lei JH, Liang J, Gong X, Xiao XQ, Chen Z, Peng F. Analysis of Transmission Routes of Hepatitis C Virus Based on Virus Genotyping in 341 Cases with Different Suspected Initial Infection Time Points in Hunan Province, China. Med Sci Monit 2018;24:5232-41. [PMID: 30055000 DOI: 10.12659/MSM.907424] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
135 Grebely J, Haire B, Taylor LE, Macneill P, Litwin AH, Swan T, Byrne J, Levin J, Bruggmann P, Dore GJ; International Network for Hepatitis in Substance Users. Excluding people who use drugs or alcohol from access to hepatitis C treatments – Is this fair, given the available data? J Hepatol 2015;63:779-82. [PMID: 26254264 DOI: 10.1016/j.jhep.2015.06.014] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
136 Alavian SM, Hajariazdeh BM, Kabir AA, Lankarani KB. Hepatitis B virus infection in Iran: a systematic review. Hepat Mon. 2008;8:281-294. [PMID: 23270391 DOI: 10.1186/1471-2334-12-378] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
137 Busschots D, Kremer C, Bielen R, Koc ÖM, Heyens L, Dercon E, Verrando R, Windelinckx T, Maertens G, Bourgeois S, Hens N, Matheï C, Robaeys G. Identification and treatment of viral hepatitis C in persons who use drugs: a prospective, multicenter outreach study in Flanders, Belgium. Harm Reduct J 2021;18:54. [PMID: 34001145 DOI: 10.1186/s12954-021-00502-7] [Reference Citation Analysis]
138 Bach P, Walton G, Hayashi K, Milloy MJ, Dong H, Kerr T, Montaner J, Wood E. Benzodiazepine Use and Hepatitis C Seroconversion in a Cohort of Persons Who Inject Drugs. Am J Public Health 2016;106:1067-72. [PMID: 26985601 DOI: 10.2105/AJPH.2016.303090] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
139 Litwin AH, Jost J, Wagner K, Heo M, Karasz A, Feinberg J, Kim AY, Lum PJ, Mehta SH, Taylor LE, Tsui JI, Pericot-Valverde I, Page K; HERO Study Group. Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: The HERO study. Contemp Clin Trials 2019;87:105859. [PMID: 31669450 DOI: 10.1016/j.cct.2019.105859] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
140 Clement ME, Collins LF, Wilder JM, Mugavero M, Barker T, Naggie S. Hepatitis C Virus Elimination in the Human Immunodeficiency Virus-Coinfected Population: Leveraging the Existing Human Immunodeficiency Virus Infrastructure. Infect Dis Clin North Am 2018;32:407-23. [PMID: 29778263 DOI: 10.1016/j.idc.2018.02.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
141 Bruening J, Weigel B, Gerold G. The Role of Type III Interferons in Hepatitis C Virus Infection and Therapy. J Immunol Res 2017;2017:7232361. [PMID: 28255563 DOI: 10.1155/2017/7232361] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
142 Grebely J, Litwin A, Dore GJ. Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all. J Viral Hepat 2016;23:664-6. [PMID: 27272285 DOI: 10.1111/jvh.12550] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
143 Trickey A, May MT, Davies C, Qureshi H, Hamid S, Mahmood H, Saeed Q, Hickman M, Glass N, Averhoff F, Vickerman P. Importance and Contribution of Community, Social, and Healthcare Risk Factors for Hepatitis C Infection in Pakistan. Am J Trop Med Hyg 2017;97:1920-8. [PMID: 29141707 DOI: 10.4269/ajtmh.17-0019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
144 Taherkhani R, Farshadpour F. Epidemiology of hepatitis C virus in Iran. World J Gastroenterol 2015; 21(38): 10790-10810 [PMID: 26478671 DOI: 10.3748/wjg.v21.i38.10790] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 43] [Article Influence: 7.6] [Reference Citation Analysis]
145 Ford C, Bressan J. Ending the mass criminalisation of people who use drugs: a necessary component of the public health response to hepatitis C. BMC Infect Dis 2014;14 Suppl 6:S4. [PMID: 25253223 DOI: 10.1186/1471-2334-14-S6-S4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
146 Ziff J, Vu T, Dvir D, Riazi F, Toribio W, Oster S, Sigel K, Weiss J. Predictors of hepatitis C treatment outcomes in a harm reduction-focused primary care program in New York City. Harm Reduct J 2021;18:38. [PMID: 33789691 DOI: 10.1186/s12954-021-00486-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
147 Pericàs JM, Bromberg DJ, Ocampo D, Schatz E, Wawer I, Wysocki P, Safreed-Harmon K, Lazarus JV. Hepatitis C services at harm reduction centres in the European Union: a 28-country survey. Harm Reduct J 2019;16:20. [PMID: 30898122 DOI: 10.1186/s12954-019-0290-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
148 Janulis P. The micro-social risk environment for injection drug use: An event specific analysis of dyadic, situational, and network predictors of injection risk behavior. Int J Drug Policy 2016;27:56-64. [PMID: 26530884 DOI: 10.1016/j.drugpo.2015.09.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
149 Stephens DB, Havens JR. Predictors of alcohol use among rural drug users after disclosure of hepatitis C virus status. J Stud Alcohol Drugs 2013;74:386-95. [PMID: 23490567 DOI: 10.15288/jsad.2013.74.386] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
150 Parikh MP, Octaria R, Kainer MA. Methicillin-Resistant Staphylococcus aureus Bloodstream Infections and Injection Drug Use, Tennessee, USA, 2015-2017. Emerg Infect Dis 2020;26. [PMID: 32091385 DOI: 10.3201/eid2603.191408] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
151 Cox AL, Thomas DL. Hepatitis C virus vaccines among people who inject drugs. Clin Infect Dis. 2013;57 Suppl 2:S46-S50. [PMID: 23884065 DOI: 10.1093/cid/cit329] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
152 Witkowska McConnell W, Davis C, Sabir SR, Garrett A, Bradley-Stewart A, Jajesniak P, Reboud J, Xu G, Yang Z, Gunson R, Thomson EC, Cooper JM. Paper microfluidic implementation of loop mediated isothermal amplification for early diagnosis of hepatitis C virus. Nat Commun 2021;12:6994. [PMID: 34848705 DOI: 10.1038/s41467-021-27076-z] [Reference Citation Analysis]
153 Chaabna K, Kouyoumjian SP, Abu-Raddad LJ. Hepatitis C Virus Epidemiology in Djibouti, Somalia, Sudan, and Yemen: Systematic Review and Meta-Analysis. PLoS One. 2016;11:e0149966. [PMID: 26900839 DOI: 10.1371/journal.pone.0149966] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
154 Cortina-Borja M, Williams D, Peckham CS, Bailey H, Thorne C. Hepatitis C virus seroprevalence in pregnant women delivering live-born infants in North Thames, England in 2012. Epidemiol Infect 2016;144:627-34. [PMID: 26178148 DOI: 10.1017/S0950268815001557] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
155 Kakchapati S, Maharjan M, Rawal BB, Dixit SM. Social determinants and risk behaviors associated with prevalent Hepatitis C and HIV/HCV co-infection among male injection drug users in Nepal. Arch Public Health 2017;75:39. [PMID: 28878895 DOI: 10.1186/s13690-017-0206-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
156 Hawks L, Norton BL, Cunningham CO, Fox AD. The Hepatitis C virus treatment cascade at an urban postincarceration transitions clinic. J Viral Hepat 2016;23:473-8. [PMID: 26856967 DOI: 10.1111/jvh.12512] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
157 Azim T, Bontell I, Strathdee SA. Women, drugs and HIV. Int J Drug Policy 2015;26 Suppl 1:S16-21. [PMID: 25277726 DOI: 10.1016/j.drugpo.2014.09.003] [Cited by in Crossref: 75] [Cited by in F6Publishing: 68] [Article Influence: 9.4] [Reference Citation Analysis]
158 Waheed Y, Najmi MH, Aziz H, Waheed H, Imran M, Safi SZ. Prevalence of hepatitis C in people who inject drugs in the cities of Rawalpindi and Islamabad, Pakistan. Biomed Rep 2017;7:263-6. [PMID: 28894573 DOI: 10.3892/br.2017.959] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
159 Huang P, Zhu LG, Zhu YF, Yue M, Su J, Zhu FC, Yang HT, Zhang Y, Shen HB, Yu RB, Zhai XJ, Peng ZH. Seroepidemiology of hepatitis B virus infection and impact of vaccination. World J Gastroenterol 2015; 21(25): 7842-7850 [PMID: 26167084 DOI: 10.3748/wjg.v21.i25.7842] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
160 Phillips KA, Epstein DH, Vahabzadeh M, Mezghanni M, Lin JL, Preston KL. Substance use and hepatitis C: an ecological momentary assessment study. Health Psychol 2014;33:710-9. [PMID: 24977312 DOI: 10.1037/hea0000087] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
161 Dunford L, Carr MJ, Dean J, Waters A, Nguyen LT, Ta Thi TH, Thi LA, Do HD, Thi TT, Nguyen HT. Hepatitis C virus in Vietnam: high prevalence of infection in dialysis and multi-transfused patients involving diverse and novel virus variants. PLoS One. 2012;7:e41266. [PMID: 22916104 DOI: 10.1371/journal.pone.0041266] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
162 Lamb S, Kral AH, Dominguez-Gonzalez K, Wenger LD, Bluthenthal RN. Peer-to-peer injection: Demographic, drug use, and injection-related risk factors. Int J Drug Policy 2018;61:44-51. [PMID: 30388569 DOI: 10.1016/j.drugpo.2018.07.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
163 Feng HP, Guo Z, Caro L, Marshall WL, Liu F, Panebianco D, Vaddady P, Reitmann C, Jumes P, Wolford D, Fraser I, Valesky R, Martinho M, Butterton JR, Iwamoto M, Webster L, Yeh WW. No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Methadone in Participants Receiving Maintenance Opioid Agonist Therapy. Clin Transl Sci 2018;11:553-61. [PMID: 30040872 DOI: 10.1111/cts.12564] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
164 Rose R, Lamers SL, Massaccesi G, Osburn W, Ray SC, Thomas DL, Cox AL, Laeyendecker O. Complex patterns of Hepatitis-C virus longitudinal clustering in a high-risk population. Infect Genet Evol 2018;58:77-82. [PMID: 29253674 DOI: 10.1016/j.meegid.2017.12.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
165 Kranidioti H, Chatzievagelinou C, Protopapas A, Papatheodoridi M, Zisimopoulos K, Evangelidou E, Antonakaki P, Vlachogiannakos J, Triantos C, Elefsiniotis I, Goulis J, Mela M, Anagnostou O, Tsoulas C, Deutsch M, Papatheodoridis G, Manolakopoulos S. Clinical and epidemiological characteristics of hepatitis C virus-infected people who inject drugs: a Greek descriptive analysis. Ann Gastroenterol. 2018;31:598-603. [PMID: 30174397 DOI: 10.20524/aog.2018.0293] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
166 Zhang F, Zhu H, Wu Y, Dou Z, Zhang Y, Kleinman N, Bulterys M, Wu Z, Ma Y, Zhao D. HIV, hepatitis B virus, and hepatitis C virus co-infection in patients in the China National Free Antiretroviral Treatment Program, 2010-12: a retrospective observational cohort study. Lancet Infect Dis. 2014;14:1065-1072. [PMID: 25303841 DOI: 10.1016/s1473-3099(14)70946-6] [Cited by in Crossref: 69] [Cited by in F6Publishing: 44] [Article Influence: 8.6] [Reference Citation Analysis]
167 Spies FS, de Oliveira MB, Krug MS, Severo CB, Severo LC, Vainstein MH. Cryptococcosis in patients living with hepatitis C and B viruses. Mycopathologia 2015;179:307-12. [PMID: 25528539 DOI: 10.1007/s11046-014-9843-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
168 Grubyte S, Urboniene J, Nedzinskiene L, Jancoriene L. The Epidemiological Patterns of Hepatitis C in Lithuania: Changes in Surveillance from 2005 to 2018. Medicina (Kaunas) 2021;57:1120. [PMID: 34684157 DOI: 10.3390/medicina57101120] [Reference Citation Analysis]
169 Makiani MJ, Davoodian P, Abedi F, Hossini M, Zare S, Rahimi S, Jahanshahi KA, Eftekhari TE. AIDS and hepatitis B and C high risk behaviors among 15 to 45 years old individuals in Bandar Abbas (Iran) in 2012. Electron Physician 2014;6:884-9. [PMID: 25763163 DOI: 10.14661/2014.883-889] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
170 Crowley D, Cullen W, Laird E, Lambert JS, Mc Hugh T, Murphy C, Van Hout MC. Exploring Patient Characteristics and Barriers to Hepatitis C Treatment in Patients on Opioid Substitution Treatment Attending a Community Based Fibro-scanning Clinic. J Transl Int Med 2017;5:112-9. [PMID: 28721344 DOI: 10.1515/jtim-2017-0017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
171 Amiri FB, Gouya MM, Saifi M, Rohani M, Tabarsi P, Sedaghat A, Fahimfar N, Memarnejadian A, Aghasadeghi MR, Haghdoost AA, Jahanbakhsh F, Nasehi M, Mostafavi E. Vulnerability of homeless people in Tehran, Iran, to HIV, tuberculosis and viral hepatitis. PLoS One 2014;9:e98742. [PMID: 24896247 DOI: 10.1371/journal.pone.0098742] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
172 Hagan H, Neurer J, Jordan AE, Des Jarlais DC, Wu J, Dombrowski K, Khan B, Braithwaite RS, Kessler J. Hepatitis C virus infection among HIV-positive men who have sex with men: protocol for a systematic review and meta-analysis. Syst Rev 2014;3:31. [PMID: 24669911 DOI: 10.1186/2046-4053-3-31] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
173 Meijerink H, White RA, Løvlie A, de Blasio BF, Dalgard O, Amundsen EJ, Melum E, Kløvstad H. Modelling the burden of hepatitis C infection among people who inject drugs in Norway, 1973-2030. BMC Infect Dis 2017;17:541. [PMID: 28774261 DOI: 10.1186/s12879-017-2631-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
174 Garimella T, You X, Wang R, Huang SP, Kandoussi H, Bifano M, Bertz R, Eley T. A Review of Daclatasvir Drug-Drug Interactions. Adv Ther. 2016;33:1867-1884. [PMID: 27664109 DOI: 10.1007/s12325-016-0407-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
175 Badawi A, Di Giuseppe G, Gupta A, Poirier A, Arora P. Bayesian network modelling study to identify factors influencing the risk of cardiovascular disease in Canadian adults with hepatitis C virus infection. BMJ Open 2020;10:e035867. [PMID: 32371519 DOI: 10.1136/bmjopen-2019-035867] [Reference Citation Analysis]
176 Bruce RD, Moody DE, Altice FL, Gourevitch MN, Friedland GH. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Rev Clin Pharmacol 2013;6:249-69. [PMID: 23656339 DOI: 10.1586/ecp.13.18] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
177 Daw MA, Buktir Ali LA, Daw AM, Sifennasr NEM, Dau AA, Agnan MM, El-Bouzedi A; In association with the Libyan Study Group of Hepatitis & HIV. The geographic variation and spatiotemporal distribution of hepatitis C virus infection in Libya: 2007-2016. BMC Infect Dis 2018;18:594. [PMID: 30466399 DOI: 10.1186/s12879-018-3471-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
178 Hagan LM, Wolpe PR, Schinazi RF. Treatment as prevention and cure towards global eradication of hepatitis C virus. Trends Microbiol 2013;21:625-33. [PMID: 24238778 DOI: 10.1016/j.tim.2013.09.008] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
179 Fox JM, Newton R, Bedaj M, Keding A, Molyneux E, Carpenter LM, Martin F, Mutalima N. Prevalence of hepatitis C virus in mothers and their children in Malawi. Trop Med Int Health. 2015;20:638-642. [PMID: 25611121 DOI: 10.1111/tmi.12465] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
180 Horyniak D, Wagner KD, Armenta RF, Cuevas-Mota J, Hendrickson E, Garfein RS. Cross-border injection drug use and HIV and hepatitis C virus seropositivity among people who inject drugs in San Diego, California. Int J Drug Policy 2017;47:9-17. [PMID: 28683432 DOI: 10.1016/j.drugpo.2017.06.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
181 Jakupi X, M. Lunar M, Mlakar J, Matković I, P. Tavakoli N, Zafirova Ivanovska B, Vince A, Poljak M. HCV Infection among Injecting Drug Users in Prishtina, Kosovo. Hepat Mon 2018;In Press. [DOI: 10.5812/hepatmon.80189] [Reference Citation Analysis]
182 Hu T, Du Q, Ren F, Liang S, Lin D, Li J, Chen Y. Spatial analysis of the home addresses of hospital patients with hepatitis B infection or hepatoma in Shenzhen, China from 2010 to 2012. Int J Environ Res Public Health. 2014;11:3143-3155. [PMID: 24637909 DOI: 10.3390/ijerph110303143] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
183 Calcaterra SL, Keniston A, Blum J, Crume T, Binswanger IA. The Association Between Stimulant, Opioid, and Multiple Drug Use on Behavioral Health Care Utilization in a Safety-Net Health System. Subst Abus 2015;36:407-12. [PMID: 25738222 DOI: 10.1080/08897077.2014.996697] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
184 Rajabi A, Sharafi H, Alavian SM. Harm reduction program and hepatitis C prevalence in people who inject drugs (PWID) in Iran: an updated systematic review and cumulative meta-analysis. Harm Reduct J 2021;18:12. [PMID: 33482831 DOI: 10.1186/s12954-020-00441-9] [Reference Citation Analysis]
185 Zou X, Xu Y, Chen W, Xia Y, Liu Y, Gong C, Ling L. Strategies to control HIV and HCV in methadone maintenance treatment in Guangdong Province, China: a system dynamic modeling study. Subst Abuse Treat Prev Policy 2018;13:1. [PMID: 29321039 DOI: 10.1186/s13011-017-0140-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
186 Marotta PL, Gilbert L, Terlikbayeva A, Wu E, El-Bassel N. Differences by sex in associations between injection drug risks and drug crime conviction among people who inject drugs in Almaty, Kazakhstan. Int J Drug Policy 2018;60:96-106. [PMID: 30219718 DOI: 10.1016/j.drugpo.2018.07.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
187 Akiyama MJ, Kaba F, Rosner Z, Alper H, Kopolow A, Litwin AH, Venters H, MacDonald R. Correlates of Hepatitis C Virus Infection in the Targeted Testing Program of the New York City Jail System. Public Health Rep. 2017;132:41-47. [PMID: 28005477 DOI: 10.1177/0033354916679367] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
188 Panagiotoglou D, Krebs E, Min JE, Olding M, Ahamad K, Ti L, Montaner JSG, Nosyk B. Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV? Int J Drug Policy 2017;47:169-76. [PMID: 28578865 DOI: 10.1016/j.drugpo.2017.05.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
189 Corcorran MA, Ludwig-Baron N, Cheng DM, Lioznov D, Gnatienko N, Patts G, So-Armah K, Blokhina E, Bendiks S, Krupitsky E, Samet JH, Tsui JI. The Hepatitis C Continuum of Care Among HIV-Positive Persons with Heavy Alcohol Use in St. Petersburg, Russia. AIDS Behav 2021;25:2533-41. [PMID: 33730255 DOI: 10.1007/s10461-021-03214-y] [Reference Citation Analysis]
190 Ti L, Parent S, Socías ME. Integrated Models of Care for People Living with Hepatitis C Virus and a Substance Use Disorder: Protocol for a Systematic Review. JMIR Res Protoc 2018;7:e122. [PMID: 29743153 DOI: 10.2196/resprot.9532] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
191 Mittal ML, Guise A, Rafful C, Gonzalez-Zuñiga P, Davidson P, Vashishtha D, Strathdee SA, Werb D. "Another Person Was Going to Do It": The Provision of Injection Drug Use Initiation Assistance in a High-Risk U.S.-Mexico Border Region. Subst Use Misuse 2019;54:2338-50. [PMID: 31389282 DOI: 10.1080/10826084.2019.1648514] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
192 Carey KJ, Huang W, Linas BP, Tsui JI. Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders. J Subst Abuse Treat 2016;66:54-9. [PMID: 26988423 DOI: 10.1016/j.jsat.2016.01.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
193 Wang X, Tan L, Li Y, Zhang Y, Zhou D, Liu T, Hao W. HCV and HIV infection among heroin addicts in methadone maintenance treatment (MMT) and not in MMT in Changsha and Wuhan, China. PLoS One 2012;7:e45632. [PMID: 23029149 DOI: 10.1371/journal.pone.0045632] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
194 Basu D, Sharma AK, Gupta S, Nebhinani N, Kumar V. Hepatitis C virus (HCV) infection & risk factors for HCV positivity in injecting & non-injecting drug users attending a de-addiction centre in northern India. Indian J Med Res 2015;142:311-6. [PMID: 26458347 DOI: 10.4103/0971-5916.166596] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
195 Heath AJ, Kerr T, Ti L, Kaplan K, Suwannawong P, Wood E, Hayashi K. Healthcare avoidance by people who inject drugs in Bangkok, Thailand. J Public Health (Oxf) 2016;38:e301-8. [PMID: 26491067 DOI: 10.1093/pubmed/fdv143] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
196 Owusu DO, Phillips R, Owusu M, Sarfo FS, Frempong M. Increased levels of circulating IL-10 in persons recovered from hepatitis C virus (HCV) infection compared with persons with active HCV infection. BMC Res Notes 2020;13:472. [PMID: 33028385 DOI: 10.1186/s13104-020-05313-w] [Reference Citation Analysis]
197 Chemaitelly H, Mahmud S, Kouyoumjian SP, Al-Kanaani Z, Hermez JG, Abu-Raddad LJ. Who to Test for Hepatitis C Virus in the Middle East and North Africa? Hepatol Commun. 2019;3:325-339. [PMID: 30859146 DOI: 10.1002/hep4.1310] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
198 Akbarzadeh V, Mumtaz GR, Awad SF, Weiss HA, Abu-Raddad LJ. HCV prevalence can predict HIV epidemic potential among people who inject drugs: mathematical modeling analysis. BMC Public Health 2016;16:1216. [PMID: 27912737 DOI: 10.1186/s12889-016-3887-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
199 Botheju WSP, Zghyer F, Mahmud S, Terlikbayeva A, El-Bassel N, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Central Asia: Systematic review, meta-analyses, and meta-regression analyses. Sci Rep 2019;9:2090. [PMID: 30765844 DOI: 10.1038/s41598-019-38853-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
200 Dillon JF, Lazarus JV, Razavi HA. Urgent action to fight hepatitis C in people who inject drugs in Europe. Hepatol Med Policy. 2016;1:2. [PMID: 30288305 DOI: 10.1186/s41124-016-0011-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
201 Gountas I, Sypsa V, Anagnostou O, Martin N, Vickerman P, Kafetzopoulos E, Hatzakis A. Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting? Addiction 2017;112:1290-9. [PMID: 28107585 DOI: 10.1111/add.13764] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
202 Aslanidou GS, Petrides KV, Stogiannidou A. Trait Emotional Intelligence Profiles of Parents With Drug Addiction and of Their Offspring. Front Psychol 2018;9:1633. [PMID: 30233468 DOI: 10.3389/fpsyg.2018.01633] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
203 Gray Neils ME, Pfaeffle HOI, Kulatti AT, Titova A, Lyles GS, Plotnikova Y, Zorkaltseva E, Ogarkov OB, Vitko SM, Dillingham RA, Heysell SK. A Geospatial Bibliometric Review of the HIV/AIDS Epidemic in the Russian Federation. Front Public Health 2020;8:75. [PMID: 32300580 DOI: 10.3389/fpubh.2020.00075] [Reference Citation Analysis]
204 Lazarus JV, Øvrehus A, Demant J, Krohn-Dehli L, Weis N. The Copenhagen test and treat hepatitis C in a mobile clinic study: a protocol for an intervention study to enhance the HCV cascade of care for people who inject drugs (T'N'T HepC). BMJ Open 2020;10:e039724. [PMID: 33168560 DOI: 10.1136/bmjopen-2020-039724] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
205 Akiyama MJ, Cleland CM, Lizcano JA, Cherutich P, Kurth AE. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study. Lancet Infect Dis 2019;19:1255-63. [PMID: 31540840 DOI: 10.1016/S1473-3099(19)30264-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
206 Selimovic D, El-Khattouti A, Ghozlan H, Haikel Y, Abdelkader O, Hassan M. Hepatitis C virus-related hepatocellular carcinoma: An insight into molecular mechanisms and therapeutic strategies. World J Hepatol 2012; 4(12): 342-355 [PMID: 23355912 DOI: 10.4254/wjh.v4.i12.342] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
207 Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis. Clin Infect Dis. 2016;62:683-694. [PMID: 26787172 DOI: 10.1093/cid/civ948] [Cited by in Crossref: 178] [Cited by in F6Publishing: 163] [Article Influence: 29.7] [Reference Citation Analysis]
208 Imran M, Rafique H, Khan A, Malik T. A model of bi-mode transmission dynamics of hepatitis C with optimal control. Theory Biosci 2014;133:91-109. [PMID: 24374404 DOI: 10.1007/s12064-013-0197-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
209 Guichard A, Guignard R, Lert F, Roy E. Risk Factors Associated with Unsafe Injection Practices at the First Injection Episode among Intravenous Drug Users in France: Results from PrimInject, an Internet Survey. J Addict 2015;2015:507214. [PMID: 26504609 DOI: 10.1155/2015/507214] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
210 Gounder PP, Koch A, Provo G, Lovlie A, Ederth JL, Axelsson M, Archibald CP, Hanley B, Mullen A, Matheson M, Allison D, Trykker H, Hennessy TW, Kuusi M, Chulanov V, McMahon BJ. Summary of available surveillance data on hepatitis C virus infection from eight Arctic countries, 2012 to 2014. Euro Surveill 2018;23. [PMID: 30301489 DOI: 10.2807/1560-7917.ES.2018.23.40.1700408] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
211 Rashti R, Sharafi H, Alavian SM, Moradi Y, Mohamadi Bolbanabad A, Moradi G. Systematic Review and Meta-Analysis of Global Prevalence of HBsAg and HIV and HCV Antibodies among People Who Inject Drugs and Female Sex Workers. Pathogens 2020;9:E432. [PMID: 32486342 DOI: 10.3390/pathogens9060432] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
212 Hannula R, Söderholm J, Svendsen T, Skaland M, Nordbø SA, Steinum H, Damås JK. Hepatitis C outreach project and cross-sectional epidemiology in high-risk populations in Trondheim, Norway. Ther Adv Infect Dis 2021;8:20499361211053929. [PMID: 34733508 DOI: 10.1177/20499361211053929] [Reference Citation Analysis]
213 Wang C, Shi CX, Rou K, Zhao Y, Cao X, Luo W, Liu E, Wu Z. Baseline HCV Antibody Prevalence and Risk Factors among Drug Users in China's National Methadone Maintenance Treatment Program. PLoS One 2016;11:e0147922. [PMID: 26906025 DOI: 10.1371/journal.pone.0147922] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
214 de Oliveira SB, Sabidó M, Pascom ARP, Gisiviez JM, Benzaken AS, Mesquita F. State of viral hepatitis knowledge and testing uptake in Brazil: Findings from the National Survey of Knowledge, Attitudes and Practices (PCAP-2013). Hepatol Med Policy 2016;1:3. [PMID: 30288306 DOI: 10.1186/s41124-016-0003-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
215 Nong VM, Boggiano VL, Nguyen LHT, Nguyen CT, Nguyen LH, Xuan Bach T, Nguyen HV, Hoang CD, Latkin CA, Vu MTT. Ability to join the workforce and work productivity among drug users under methadone maintenance treatment in a mountainous area of Northern Vietnam: a cross-sectional study. BMJ Open 2017;7:e016153. [PMID: 28751487 DOI: 10.1136/bmjopen-2017-016153] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
216 Kinner SA, Snow K, Wirtz AL, Altice FL, Beyrer C, Dolan K. Age-Specific Global Prevalence of Hepatitis B, Hepatitis C, HIV, and Tuberculosis Among Incarcerated People: A Systematic Review. J Adolesc Health 2018;62:S18-26. [PMID: 29455713 DOI: 10.1016/j.jadohealth.2017.09.030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
217 Sheikh MY, Atla PR, Ameer A, Sadiq H, Sadler PC. Seroprevalence of Hepatitis B and C Infections among Healthy Volunteer Blood Donors in the Central California Valley. Gut Liver 2013;7:66-73. [PMID: 23423771 DOI: 10.5009/gnl.2013.7.1.66] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
218 Grebely J, Larney S, Peacock A, Colledge S, Leung J, Hickman M, Vickerman P, Blach S, Cunningham EB, Dumchev K, Lynskey M, Stone J, Trickey A, Razavi H, Mattick RP, Farrell M, Dore GJ, Degenhardt L. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Addiction 2019;114:150-66. [PMID: 30035835 DOI: 10.1111/add.14393] [Cited by in Crossref: 93] [Cited by in F6Publishing: 92] [Article Influence: 23.3] [Reference Citation Analysis]
219 Buchanan RM, Cook C, Khakoo SI, Parkes J. Testing key underlying assumptions of respondent-driven sampling within a real-world network of people who inject drugs. International Journal of Social Research Methodology. [DOI: 10.1080/13645579.2020.1857964] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
220 Heil J, Hoebe CJPA, Cals JWL, Ter Waarbeek HLG, van Loo IHM, Dukers-Muijrers NHTM. Detecting Hepatitis B and C by Combined Public Health and Primary Care Birth Cohort Testing. Ann Fam Med 2018;16:21-7. [PMID: 29311171 DOI: 10.1370/afm.2166] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
221 Maan MA, Hussain F, Jamil M. Epidemiology of hepatitis C viral infection in Faisalabad, Pakistan: a retrospective study (2010-2012). Afr Health Sci 2014;14:810-5. [PMID: 25834487 DOI: 10.4314/ahs.v14i4.6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
222 Guo Y, Gao P, Wang H, Wu J, Bai Q, Huang L, Li S, Lv M, Shi X. Risk factors of hepatitis B virus infection between vaccinated and unvaccinated groups among spouses in 2006 and 2014: a cross-sectional study in Beijing. Hum Vaccin Immunother 2020;16:148-57. [PMID: 31287778 DOI: 10.1080/21645515.2019.1640428] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
223 Hope VD, McVeigh J, Marongiu A, Evans-Brown M, Smith J, Kimergård A, Croxford S, Beynon CM, Parry JV, Bellis MA, Ncube F. Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study. BMJ Open 2013;3:e003207. [PMID: 24030866 DOI: 10.1136/bmjopen-2013-003207] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 5.7] [Reference Citation Analysis]
224 Behzadifar M, Behzadifar M, Bragazzi NL. A systematic review and meta-analysis of the prevalence of hepatitis C virus infection in people who inject drugs in Iran. BMC Public Health 2020;20:62. [PMID: 31937278 DOI: 10.1186/s12889-020-8175-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
225 Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, Lesmana CR, Sollano J, Kumar M, Jindal A. APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int. 2016;10:681-701. [PMID: 27229718 DOI: 10.1007/s12072-016-9736-3] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 8.0] [Reference Citation Analysis]
226 Coley JS, Calderon TM, Gaskill PJ, Eugenin EA, Berman JW. Dopamine increases CD14+CD16+ monocyte migration and adhesion in the context of substance abuse and HIV neuropathogenesis. PLoS One 2015;10:e0117450. [PMID: 25647501 DOI: 10.1371/journal.pone.0117450] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
227 Plauzolles A, Lucas M, Gaudieri S. Influence of host resistance on viral adaptation: hepatitis C virus as a case study. Infect Drug Resist 2015;8:63-74. [PMID: 25897250 DOI: 10.2147/IDR.S49891] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
228 Alanko Blomé M, Björkman P, Molnegren V, Höglund P, Widell A. Hepatitis C viremia patterns in incident hepatitis C infection and one year later in 150 prospectively tested persons who inject drugs. PLoS One 2014;9:e97022. [PMID: 24830647 DOI: 10.1371/journal.pone.0097022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
229 Schillie S, Vellozzi C, Reingold A, Harris A, Haber P, Ward JW, Nelson NP. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018;67:1-31. [PMID: 29939980 DOI: 10.15585/mmwr.rr6701a1] [Cited by in Crossref: 216] [Cited by in F6Publishing: 201] [Article Influence: 54.0] [Reference Citation Analysis]
230 Zhao X, Shi X, Lv M, Yuan B, Wu J. Prevalence and factors associated with hepatitis B virus infection among household members: a cross-sectional study in Beijing. Hum Vaccin Immunother 2021;17:1818-24. [PMID: 33606606 DOI: 10.1080/21645515.2020.1847951] [Reference Citation Analysis]
231 Sangal RB, Taylor LE, Gillani F, Poppas A, Klinger JR, Ventetuolo CE. Risk of echocardiographic pulmonary hypertension in individuals with human immunodeficiency virus-hepatitis C virus coinfection. Ann Am Thorac Soc 2014;11:1553-9. [PMID: 25375659 DOI: 10.1513/AnnalsATS.201405-225OC] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 2.1] [Reference Citation Analysis]
232 Uusküla A, Raag M, Vorobjov S, Jarlais DD. Another frontier for harm reduction: contraceptive needs of females who inject drugs in Estonia, a cross-sectional study. Harm Reduct J 2018;15:10. [PMID: 29506538 DOI: 10.1186/s12954-018-0215-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
233 Patel AA, Bui A, Prohl E, Bhattacharya D, Wang S, Branch AD, Perumalswami PV. Innovations in Hepatitis C Screening and Treatment. Hepatol Commun 2021;5:371-86. [PMID: 33681673 DOI: 10.1002/hep4.1646] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
234 de Martel C, Maucort-Boulch D, Plummer M, Franceschi S. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology. 2015;62:1190-1200. [PMID: 26146815 DOI: 10.1002/hep.27969] [Cited by in Crossref: 230] [Cited by in F6Publishing: 235] [Article Influence: 38.3] [Reference Citation Analysis]
235 Hope VD, Harris R, McVeigh J, Cullen KJ, Smith J, Parry JV, DeAngelis D, Ncube F. Risk of HIV and Hepatitis B and C Over Time Among Men Who Inject Image and Performance Enhancing Drugs in England and Wales: Results From Cross-Sectional Prevalence Surveys, 1992-2013. J Acquir Immune Defic Syndr 2016;71:331-7. [PMID: 26361173 DOI: 10.1097/QAI.0000000000000835] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 3.2] [Reference Citation Analysis]
236 Spada E, Rezza G, Garbuglia AR, Lombardo FL, Zuccaro O, Menniti Ippolito F, Cupellaro E, Capone S, Capobianchi MR, Nicosia A, Cortese R, Folgori A, Mele A; Collaborative Study Group. Incidence and Risk Factors for Hepatitis C Virus Infection among Illicit Drug Users in Italy. J Urban Health 2018;95:99-110. [PMID: 29204843 DOI: 10.1007/s11524-017-0207-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
237 Melhem NM, Rahhal N, Charide R, Kreidieh K, El-Khatib R. Human immunodeficiency virus and viral hepatitis among high-risk groups: Understanding the knowledge gap in the Middle East and North Africa Region. World J Hepatol 2015; 7(25): 2619-2630 [PMID: 26557955 DOI: 10.4254/wjh.v7.i25.2619] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
238 Sazzad HMS, Luby SP, Labrique AB, Kamili S, Hayden TM, Kamili NA, Teo CG, Gurley ES. Risk Factors Associated with Blood Exposure for Sporadic Hepatitis E in Dhaka, Bangladesh. Am J Trop Med Hyg 2017;97:1437-44. [PMID: 28820721 DOI: 10.4269/ajtmh.17-0261] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
239 Rácz J, Csák R, Lisznyai S. Transition from “old” injected drugs to mephedrone in an urban micro segregate in Budapest, Hungary: a qualitative analysis. Journal of Substance Use 2015;20:178-86. [DOI: 10.3109/14659891.2014.895872] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
240 Kileng H, Gutteberg T, Goll R, Paulssen EJ. Screening for hepatitis C in a general adult population in a low-prevalence area: the Tromsø study. BMC Infect Dis 2019;19:189. [PMID: 30808290 DOI: 10.1186/s12879-019-3832-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
241 Grebely J, Lima VD, Marshall BD, Milloy MJ, DeBeck K, Montaner J, Simo A, Krajden M, Dore GJ, Kerr T, Wood E. Declining incidence of hepatitis C virus infection among people who inject drugs in a Canadian setting, 1996-2012. PLoS One 2014;9:e97726. [PMID: 24897109 DOI: 10.1371/journal.pone.0097726] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
242 Janulis P. Improving measurement of injection drug risk behavior using item response theory. Am J Drug Alcohol Abuse 2014;40:143-50. [PMID: 24266632 DOI: 10.3109/00952990.2013.848212] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
243 Coppock D, Chou E, Gracely E, Gross R, Heun-Lee D. Hepatitis C antibody screening and determinants of initial and duplicate screening in the baby boomer patients of six urban primary care clinics. PLoS One 2020;15:e0235778. [PMID: 32645083 DOI: 10.1371/journal.pone.0235778] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
244 Horyniak D, Strathdee SA, West BS, Meacham M, Rangel G, Gaines TL. Predictors of injecting cessation among a cohort of people who inject drugs in Tijuana, Mexico. Drug Alcohol Depend 2018;185:298-304. [PMID: 29482055 DOI: 10.1016/j.drugalcdep.2017.12.034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
245 Young S, Wood E, Milloy MJ, DeBeck K, Dobrer S, Nosova E, Kerr T, Hayashi PhD K. Hepatitis C cascade of care among people who inject drugs in Vancouver, Canada. Subst Abus 2018;39:461-8. [PMID: 29949450 DOI: 10.1080/08897077.2018.1485128] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
246 Chaabna K, Kouyoumjian SP, Abu-Raddad LJ. Hepatitis C Virus Epidemiology in Djibouti, Somalia, Sudan, and Yemen: Systematic Review and Meta-Analysis. PLoS One. 2016;11:e0149966. [PMID: 26900839 DOI: 10.1371/journal.pone.0149966].] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
247 McFall AM, Solomon SS, Lucas GM, Celentano DD, Srikrishnan AK, Kumar MS, Mehta SH. Epidemiology of HIV and hepatitis C infection among women who inject drugs in Northeast India: a respondent-driven sampling study. Addiction 2017;112:1480-7. [PMID: 28317210 DOI: 10.1111/add.13821] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
248 Bagchi AD. A Structural Competency Curriculum for Primary Care Providers to Address the Opioid Use Disorder, HIV, and Hepatitis C Syndemic. Front Public Health 2020;8:210. [PMID: 32582612 DOI: 10.3389/fpubh.2020.00210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
249 Castro E, Roger E. Hepatitis C virus/human T lymphotropic virus 1/2 co-infection: Regional burden and virological outcomes in people who inject drugs. World J Virol 2016; 5(2): 68-72 [PMID: 27175351 DOI: 10.5501/wjv.v5.i2.68] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
250 Ray Saraswati L, Sarna A, Sebastian MP, Sharma V, Madan I, Thior I, Pulerwitz J, Tun W. HIV, Hepatitis B and C among people who inject drugs: high prevalence of HIV and Hepatitis C RNA positive infections observed in Delhi, India. BMC Public Health 2015;15:726. [PMID: 26223866 DOI: 10.1186/s12889-015-2003-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
251 Crowley D, Van Hout MC, Murphy C, Kelly E, Lambert JS, Cullen W. Hepatitis C virus screening and treatment in Irish prisons from nurse managers' perspectives - a qualitative exploration. BMC Nurs 2019;18:23. [PMID: 31210751 DOI: 10.1186/s12912-019-0347-x] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
252 Ndombi EM, Budambula V, Webale MK, Musumba FO, Wesongah JO, Mibei E, Ahmed AA, Lihana R, Were T. Serum adiponectin in HIV-1 and hepatitis C virus mono- and co-infected Kenyan injection drug users. Endocr Connect 2015;4:223-32. [PMID: 26306727 DOI: 10.1530/EC-15-0071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
253 Tengan FM, Ibrahim KY, Dantas BP, Manchiero C, Magri MC, Bernardo WM. Seroprevalence of hepatitis C virus among people living with HIV/AIDS in Latin America and the Caribbean: a systematic review. BMC Infect Dis 2016;16:663. [PMID: 27829381 DOI: 10.1186/s12879-016-1988-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
254 Stasi C, Silvestri C, Voller F. Emerging Trends in Epidemiology of Hepatitis B Virus Infection. J Clin Transl Hepatol 2017;5:272-6. [PMID: 28936408 DOI: 10.14218/JCTH.2017.00010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 12] [Article Influence: 0.2] [Reference Citation Analysis]
255 Blackard JT, Brown JL, Lyons MS. Synthetic Opioid Use and Common Injection-associated Viruses: Expanding the Translational Research Agenda. Curr HIV Res 2019;17:94-101. [PMID: 31210115 DOI: 10.2174/1570162X17666190618154534] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
256 Granados-García V, Flores YN, Díaz-Trejo LI, Méndez-Sánchez L, Liu S, Salinas-Escudero G, Toledano-Toledano F, Salmerón J. Estimating the prevalence of hepatitis C among intravenous drug users in upper middle income countries: A systematic review and meta-analysis. PLoS One 2019;14:e0212558. [PMID: 30807590 DOI: 10.1371/journal.pone.0212558] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
257 Flynn JK, Sacks-Davis R, Higgs P, Aitken C, Moneer S, Suppiah V, Tracy L, Ffrench R, Bowden S, Drummer H, George J, Bharadwaj M, Hellard M. Detection of HCV-Specific IFN-γ Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users. Hepat Mon 2014;14:e14678. [PMID: 24497881 DOI: 10.5812/hepatmon.14678] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
258 Yang J, Zhang Y, Luo L, Meng R, Yu C. Global Mortality Burden of Cirrhosis and Liver Cancer Attributable to Injection Drug Use, 1990-2016: An Age-Period-Cohort and Spatial Autocorrelation Analysis. Int J Environ Res Public Health 2018;15:E170. [PMID: 29361804 DOI: 10.3390/ijerph15010170] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
259 Spina A, Eramova I, Lazarus JV. Policy responses to viral hepatitis B and C among people who inject drugs in Member States of the WHO European region: a sub-analysis of the WHO 2013 global hepatitis policy survey. BMC Infect Dis 2014;14 Suppl 6:S15. [PMID: 25252705 DOI: 10.1186/1471-2334-14-S6-S15] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
260 Gondeau C, Pageaux GP, Larrey D. Hepatitis C virus infection: Are there still specific problems with genotype 3? World J Gastroenterol 2015; 21(42): 12101-12113 [PMID: 26576095 DOI: 10.3748/wjg.v21.i42.12101] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
261 Semenza JC, Rocklöv J, Penttinen P, Lindgren E. Observed and projected drivers of emerging infectious diseases in Europe. Ann N Y Acad Sci 2016;1382:73-83. [PMID: 27434370 DOI: 10.1111/nyas.13132] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
262 Garriga C, Manzanares-Laya S, García de Olalla P, Gorrindo P, Lens S, Solà R, Martínez-Rebollar M, Laguno M, Navarro J, Torras X, Gurguí M, Barberá MJ, Quer J, Masdeu E, Simón P, Ros M, de Andrés A, Caylà JA. Evolution of acute hepatitis C virus infection in a large European city: Trends and new patterns. PLoS One 2017;12:e0187893. [PMID: 29135988 DOI: 10.1371/journal.pone.0187893] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
263 Iversen J, Page K, Madden A, Maher L. HIV, HCV, and Health-Related Harms Among Women Who Inject Drugs: Implications for Prevention and Treatment. J Acquir Immune Defic Syndr 2015;69 Suppl 2:S176-81. [PMID: 25978485 DOI: 10.1097/QAI.0000000000000659] [Cited by in Crossref: 75] [Cited by in F6Publishing: 47] [Article Influence: 10.7] [Reference Citation Analysis]
264 Kalkeri G, Lin C, Gopilan J, Sloan K, Rijnbrand R, Kwong AD. Restoration of the activated Rig-I pathway in hepatitis C virus (HCV) replicon cells by HCV protease, polymerase, and NS5A inhibitors in vitro at clinically relevant concentrations. Antimicrob Agents Chemother 2013;57:4417-26. [PMID: 23836176 DOI: 10.1128/AAC.00399-13] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
265 McNeil R, Kerr T, Anderson S, Maher L, Keewatin C, Milloy MJ, Wood E, Small W. Negotiating structural vulnerability following regulatory changes to a provincial methadone program in Vancouver, Canada: A qualitative study. Soc Sci Med 2015;133:168-76. [PMID: 25875323 DOI: 10.1016/j.socscimed.2015.04.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
266 Dias C, Pipa S, Mota M. Acute hepatitis C from heterosexual transmission. IDCases 2018;14:e00448. [PMID: 30191131 DOI: 10.1016/j.idcr.2018.e00448] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
267 Zehender G, Ebranati E, Gabanelli E, Shkjezi R, Lai A, Sorrentino C, Lo Presti A, Basho M, Bruno R, Tanzi E, Bino S, Ciccozzi M, Galli M. Spatial and temporal dynamics of hepatitis B virus D genotype in Europe and the Mediterranean Basin. PLoS One. 2012;7:e37198. [PMID: 22662136 DOI: 10.1371/journal.pone.0037198] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 4.2] [Reference Citation Analysis]
268 Aas CF, Vold JH, Skurtveit S, Odsbu I, Chalabianloo F, Økland JM, Leiva RAM, Vickerman P, Johansson KA, Fadnes LT. On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: a prospective cohort study from 2013 to 2017. BMJ Open 2020;10:e036355. [PMID: 32847908 DOI: 10.1136/bmjopen-2019-036355] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
269 Charlson FJ, Baxter AJ, Dua T, Degenhardt L, Whiteford HA, Vos T. Excess mortality from mental, neurological and substance use disorders in the Global Burden of Disease Study 2010. Epidemiol Psychiatr Sci 2015;24:121-40. [PMID: 25497332 DOI: 10.1017/S2045796014000687] [Cited by in Crossref: 49] [Cited by in F6Publishing: 20] [Article Influence: 6.1] [Reference Citation Analysis]
270 Khatib A, Matiko E, Khalid F, Welty S, Ali A, Othman A, Haji S, Dahoma M, Rutherford G. HIV and hepatitis B and C co-infection among people who inject drugs in Zanzibar. BMC Public Health 2017;17:917. [PMID: 29183287 DOI: 10.1186/s12889-017-4933-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
271 Ridruejo E, Bessone F, Daruich JR, Estes C, Gadano AC, Razavi H, Villamil FG, Silva MO. Hepatitis C virus infection in Argentina: Burden of chronic disease. World J Hepatol 2016; 8(15): 649-658 [PMID: 27239258 DOI: 10.4254/wjh.v8.i15.649] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
272 Marano G, Vaglio S, Pupella S, Facco G, Bianchi M, Calizzani G, Candura F, Catalano L, Farina B, Lanzoni M. Hepatitis E: an old infection with new implications. Blood Transfus. 2015;13:6-17. [PMID: 25369613 DOI: 10.2450/2014.0063-14] [Cited by in F6Publishing: 18] [Reference Citation Analysis]
273 Ferreira PM, Guimarães RA, Souza CM, Guimarães LC, Barros CV, Caetano KA, Rezza G, Spadoni L, Brunini SM. Exposure to hepatitis C virus in homeless men in Central Brazil: a cross-sectional study. BMC Public Health 2017;17:90. [PMID: 28100196 DOI: 10.1186/s12889-016-3952-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
274 Petković B, Kesić S, Pešić V. Critical View on the Usage of Ribavirin in Already Existing Psychostimulant-Use Disorder. Curr Pharm Des 2020;26:466-84. [PMID: 31939725 DOI: 10.2174/1381612826666200115094642] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
275 Aye NS, Oo MM, Harries AD, Mon MM, Hone S, Oo HN, Wan NMA. HIV, HBV and HCV in people who inject drugs and are placed on methadone maintenance therapy, Yangon, Myanmar. Public Health Action 2018;8:202-10. [PMID: 30775281 DOI: 10.5588/pha.18.0050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
276 Rapoud D, Quillet C, Pham Minh K, Vu Hai V, Nguyen Thanh B, Nham Thi Tuyet T, Tran Thi H, Molès JP, Vallo R, Michel L, Feelemyer J, Weiss L, Lemoine M, Vickerman P, Fraser H, Duong Thi H, Khuat Thi Hai O, Des Jarlais D, Nagot N, Laureillard D; DRIVE-C Study Group. Towards HCV elimination among people who inject drugs in Hai Phong, Vietnam: study protocol for an effectiveness-implementation trial evaluating an integrated model of HCV care (DRIVE-C: DRug use & Infections in ViEtnam-hepatitis C). BMJ Open 2020;10:e039234. [PMID: 33208326 DOI: 10.1136/bmjopen-2020-039234] [Reference Citation Analysis]
277 Thinh VT, Phuong DT, Hoa VD, Giang LM. Reported Low Uptake of HCV Testing among People Who Inject Drugs in Urban Vietnam. Biomed Res Int 2020;2020:3701379. [PMID: 33274205 DOI: 10.1155/2020/3701379] [Reference Citation Analysis]
278 Li L, Assanangkornchai S, Duo L, McNeil E, Li J. Risk behaviors, prevalence of HIV and hepatitis C virus infection and population size of current injection drug users in a China-Myanmar border city: results from a Respondent-Driven Sampling Survey in 2012. PLoS One 2014;9:e106899. [PMID: 25203256 DOI: 10.1371/journal.pone.0106899] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
279 Go VF, Minh NL, Frangakis C, Ha TV, Latkin CA, Sripaipan T, Davis W, Zelaya C, Ngoc NP, Quan VM. Decreased injecting is associated with increased alcohol consumption among injecting drug users in northern Vietnam. Int J Drug Policy 2013;24:304-11. [PMID: 23332981 DOI: 10.1016/j.drugpo.2012.12.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
280 Rozada I, Coombs D, Lima VD. Conditions for eradicating hepatitis C in people who inject drugs: A fibrosis aware model of hepatitis C virus transmission. J Theor Biol 2016;395:31-9. [PMID: 26845310 DOI: 10.1016/j.jtbi.2016.01.030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
281 Norton BL, Fleming J, Bachhuber MA, Steinman M, DeLuca J, Cunningham CO, Johnson N, Laraque F, Litwin AH. High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic. Int J Drug Policy 2017;47:196-201. [PMID: 28811158 DOI: 10.1016/j.drugpo.2017.07.021] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 12.4] [Reference Citation Analysis]
282 Sacks-Davis R, Daraganova G, Aitken C, Higgs P, Tracy L, Bowden S, Jenkinson R, Rolls D, Pattison P, Robins G, Grebely J, Barry A, Hellard M. Hepatitis C virus phylogenetic clustering is associated with the social-injecting network in a cohort of people who inject drugs. PLoS One 2012;7:e47335. [PMID: 23110068 DOI: 10.1371/journal.pone.0047335] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 5.5] [Reference Citation Analysis]
283 Didiya R, Gyenwali D, Pokhrel TN, Devkota S, Rai AB, Shedain PR, Sharma M, Shrestha MK, Imran M, Kadirov Z, Dahal BP, K C P, Ojha S, Pokhrel KN. Community led testing among people who inject drugs: A community centered model to find new cases of HIV and Hepatitis C in Nepal. PLoS One 2021;16:e0252490. [PMID: 34048484 DOI: 10.1371/journal.pone.0252490] [Reference Citation Analysis]
284 Ward KM, McCormick SD, Sulkowski M, Latkin C, Chander G, Falade-Nwulia O. Perceptions of network based recruitment for hepatitis C testing and treatment among persons who inject drugs: a qualitative exploration. Int J Drug Policy 2021;88:103019. [PMID: 33160152 DOI: 10.1016/j.drugpo.2020.103019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
285 Stone KA. Reviewing harm reduction for people who inject drugs in Asia: the necessity for growth. Harm Reduct J 2015;12:32. [PMID: 26472335 DOI: 10.1186/s12954-015-0066-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
286 Toro-Tobón D, Berbesi-Fernandez D, Mateu-Gelabert P, Segura-Cardona ÁM, Montoya-Vélez LP. Drug dealing and drug using behaviors among people who inject drugs in Colombia: A cross-sectional study. J Subst Use 2017;22:630-6. [PMID: 31551662 DOI: 10.1080/14659891.2017.1296039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
287 Oliveira-Filho AB, Santos FJA, Silva FQ, Raiol NC, Costa CCS, Piauiense JNF, Martins LC, Cardoso YMN, Di Miceli JFF, Resque RL, Silva-Oliveira GC, Pinheiro LML, Machado LFA, Pinho JRR, Lemos JAR, Kupek E, Fischer B. Hepatitis C virus infection status and associated factors among a multi-site sample of people who used illicit drugs in the Amazon region. BMC Infect Dis 2019;19:634. [PMID: 31315569 DOI: 10.1186/s12879-019-4270-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
288 Grebely J, Morris MD, Rice TM, Bruneau J, Cox AL, Kim AY, McGovern BH, Shoukry NH, Lauer G, Maher L, Lloyd AR, Hellard M, Prins M, Dore GJ, Page K; InC Study Group. Cohort profile: the international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) study. Int J Epidemiol 2013;42:1649-59. [PMID: 23203695 DOI: 10.1093/ije/dys167] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
289 Akhtar AM, Majeed S, Jamil M, Rehman A, Majeed S. Hepatitis-C virus infection among injecting drug users in Lahore, Pakistan: A cross sectional study. Pak J Med Sci 2016;32:373-8. [PMID: 27182243 DOI: 10.12669/pjms.322.9038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
290 Spelman T, Morris MD, Zang G, Rice T, Page K, Maher L, Lloyd A, Grebely J, Dore GJ, Kim AY, Shoukry NH, Hellard M, Bruneau J; International Collaborative of Incident HIV and Hepatitis C in Injecting Cohorts (InC3 Study). A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs. J Epidemiol Community Health 2015;69:745-52. [PMID: 25814695 DOI: 10.1136/jech-2014-205224] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
291 Naseer F, Mukhtar A, Ahmed A, Raza A. Hepatitis C diagnostic management gap in Pakistan—Clinicians’ knowledge impacting public health. J Public Health 2016;24:299-305. [DOI: 10.1007/s10389-016-0725-8] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
292 Masson CL, Delucchi KL, McKnight C, Hettema J, Khalili M, Min A, Jordan AE, Pepper N, Hall J, Hengl NS, Young C, Shopshire MS, Manuel JK, Coffin L, Hammer H, Shapiro B, Seewald RM, Bodenheimer HC Jr, Sorensen JL, Des Jarlais DC, Perlman DC. A randomized trial of a hepatitis care coordination model in methadone maintenance treatment. Am J Public Health 2013;103:e81-8. [PMID: 23947319 DOI: 10.2105/AJPH.2013.301458] [Cited by in Crossref: 61] [Cited by in F6Publishing: 38] [Article Influence: 6.8] [Reference Citation Analysis]
293 Damas J, Storm M, Pandey LR, Marrone G, Deuba K. Prevalence of HIV, Hepatitis C and its related risk behaviours among women who inject drugs in the Kathmandu Valley, Nepal: a cross-sectional study. Ther Adv Infect Dis 2021;8:20499361211062107. [PMID: 34881024 DOI: 10.1177/20499361211062107] [Reference Citation Analysis]
294 Schulte M, Liang D, Wu F, Lan YC, Tsay W, Du J, Zhao M, Li X, Hser YI. A Smartphone Application Supporting Recovery from Heroin Addiction: Perspectives of Patients and Providers in China, Taiwan, and the USA. J Neuroimmune Pharmacol 2016;11:511-22. [PMID: 26846506 DOI: 10.1007/s11481-016-9653-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
295 Wade AJ, Macdonald DM, Doyle JS, Gordon A, Roberts SK, Thompson AJ, Hellard ME. The Cascade of Care for an Australian Community-Based Hepatitis C Treatment Service. PLoS One 2015;10:e0142770. [PMID: 26562516 DOI: 10.1371/journal.pone.0142770] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
296 Aas CF, Vold JH, Skurtveit S, Odsbu I, Chalabianloo F, Lim AG, Johansson KA, Fadnes LT. Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017. Subst Abuse Treat Prev Policy 2020;15:44. [PMID: 32605625 DOI: 10.1186/s13011-020-00286-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
297 Havinga P, van der Velden C, de Gee A, van der Poel A. Differences in sociodemographic, drug use and health characteristics between never, former and current injecting, problematic hard-drug users in the Netherlands. Harm Reduct J 2014;11:6. [PMID: 24524263 DOI: 10.1186/1477-7517-11-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
298 Lim AG, Walker JG, Mafirakureva N, Khalid GG, Qureshi H, Mahmood H, Trickey A, Fraser H, Aslam K, Falq G, Fortas C, Zahid H, Naveed A, Auat R, Saeed Q, Davies CF, Mukandavire C, Glass N, Maman D, Martin NK, Hickman M, May MT, Hamid S, Loarec A, Averhoff F, Vickerman P. Effects and cost of different strategies to eliminate hepatitis C virus transmission in Pakistan: a modelling analysis. Lancet Glob Health 2020;8:e440-50. [PMID: 32087176 DOI: 10.1016/S2214-109X(20)30003-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
299 Hickman M, De Angelis D, Vickerman P, Hutchinson S, Martin NK. Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence. Curr Opin Infect Dis 2015;28:576-82. [PMID: 26524330 DOI: 10.1097/QCO.0000000000000216] [Cited by in Crossref: 61] [Cited by in F6Publishing: 25] [Article Influence: 10.2] [Reference Citation Analysis]
300 Schmidbauer C, Chromy D, Schmidbauer V, Bauer D, Apata M, Nguyen D, Mandorfer M, Simbrunner B, Rieger A, Mayer F, Schmidt R, Holzmann H, Trauner M, Gschwantler M, Reiberger T. Epidemiological trends in HCV transmission and prevalence in the Viennese HIV+ population. Liver Int 2020;40:787-96. [PMID: 32017359 DOI: 10.1111/liv.14399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
301 Buchanan R, Khakoo SI, Coad J, Grellier L, Parkes J. Hepatitis C bio-behavioural surveys in people who inject drugs-a systematic review of sensitivity to the theoretical assumptions of respondent driven sampling. Harm Reduct J 2017;14:44. [PMID: 28697760 DOI: 10.1186/s12954-017-0172-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
302 Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis. 2013;57 Suppl 2:S39-S45. [PMID: 23884064 DOI: 10.1093/cid/cit296] [Cited by in Crossref: 221] [Cited by in F6Publishing: 210] [Article Influence: 27.6] [Reference Citation Analysis]
303 Strada L, Schulte B, Schmidt CS, Verthein U, Cremer-Schaeffer P, Krückeberg S, Reimer J. Epidemiology of hepatitis C virus infection among people receiving opioid substitution therapy (ECHO): study protocol. BMC Infect Dis 2015;15:563. [PMID: 26653754 DOI: 10.1186/s12879-015-1307-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
304 Valencia La Rosa J, Ryan P, Alvaro-Meca A, Troya J, Cuevas G, Gutiérrez J, Moreno S. HCV seroconversion in a cohort of people who use drugs followed in a mobile harm reduction unit in Madrid: Breaking barriers for HCV elimination. PLoS One 2018;13:e0204795. [PMID: 30281616 DOI: 10.1371/journal.pone.0204795] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
305 Mahmud S, Chemaitelly HS, Kouyoumjian SP, Al Kanaani Z, Abu-Raddad LJ. Key associations for hepatitis C virus genotypes in the Middle East and North Africa. J Med Virol 2020;92:386-93. [PMID: 31663611 DOI: 10.1002/jmv.25614] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
306 Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, Taylor LE, Dore GJ; International Network for Hepatitis in Substance Users. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Int J Drug Policy 2015;26:1028-38. [PMID: 26282715 DOI: 10.1016/j.drugpo.2015.07.005] [Cited by in Crossref: 127] [Cited by in F6Publishing: 123] [Article Influence: 18.1] [Reference Citation Analysis]
307 Reed JR, Jordan AE, Perlman DC, Smith DJ, Hagan H. The HCV care continuum among people who use drugs: protocol for a systematic review and meta-analysis. Syst Rev 2016;5:110. [PMID: 27401499 DOI: 10.1186/s13643-016-0293-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
308 Gonzalez SA, Fierer DS, Talal AH. Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection. Addict Disord Their Treat. 2017;16:S1-S23. [PMID: 28701904 DOI: 10.1097/adt.0000000000000104] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 4.2] [Reference Citation Analysis]
309 Hermosilla S, El-Bassel N, Aifah A, Terlikbayeva A, Zhumadilov Z, Berikkhanova K, Darisheva M, Gilbert L, Schluger N, Galea S. Tuberculosis report among injection drug users and their partners in Kazakhstan. Public Health 2015;129:569-75. [PMID: 25795015 DOI: 10.1016/j.puhe.2015.01.022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
310 Tsui JI, Ko SC, Krupitsky E, Lioznov D, Chaisson CE, Gnatienko N, Samet JH. Insights on the Russian HCV Care Cascade: Minimal HCV Treatment for HIV/HCV Co-infected PWID in St. Petersburg. Hepatol Med Policy 2016;1:13. [PMID: 28217368 DOI: 10.1186/s41124-016-0020-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
311 Afridi SQ, Khan N, Akmal M, Ali S, S. A, Bahadar S, Aziz A, Ali N, Hussain F, Awan F, Muddassir Ali M. Distribution of HCV Genotypes and RNA Viral Load Along with Hemato-Biochemical Analysis of HCV Patients in Rahim Yar Khan, Okara and Toba Tek Singh Districts of Punjab, Pakistan. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.58442] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
312 Li YJ, Zhu P, Liang Y, Yin WG, Xiao JH. Hepatitis B virus induces expression of cholesterol metabolism-related genes via TLR2 in HepG2 cells. World J Gastroenterol 2013; 19(14): 2262-2269 [PMID: 23599654 DOI: 10.3748/wjg.v19.i14.2262] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
313 Roux P, Fugon L, Jones JD, Comer SD. Hepatitis C infection in non-treatment-seeking heroin users: the burden of cocaine injection. Am J Addict 2013;22:613-8. [PMID: 24131170 DOI: 10.1111/j.1521-0391.2013.12058.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
314 Mumtaz GR, Weiss HA, Vickerman P, Larke N, Abu-Raddad LJ. Using hepatitis C prevalence to estimate HIV epidemic potential among people who inject drugs in the Middle East and North Africa. AIDS 2015;29:1701-10. [PMID: 26372281 DOI: 10.1097/QAD.0000000000000761] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
315 Gębska-Kuczerowska A, Kucharska I, Segiet-Swiecicka A, Kuczerowski M, Gajda R. Assessing Infection Risks among Clients and Staff Who Use Tattooing Services in Poland: An Observational Study. Int J Environ Res Public Health 2020;17:E6620. [PMID: 32932896 DOI: 10.3390/ijerph17186620] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
316 Ti L, Socías ME, Wood E, Milloy MJ, Nosova E, DeBeck K, Kerr T, Hayashi K. The impact of methadone maintenance therapy on access to regular physician care regarding hepatitis C among people who inject drugs. PLoS One 2018;13:e0194162. [PMID: 29579073 DOI: 10.1371/journal.pone.0194162] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
317 Morris MD, Bates A, Andrew E, Hahn J, Page K, Maher L. More than just someone to inject drugs with: Injecting within primary injection partnerships. Drug Alcohol Depend 2015;156:275-81. [PMID: 26460140 DOI: 10.1016/j.drugalcdep.2015.09.025] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
318 May MT, Justice AC, Birnie K, Ingle SM, Smit C, Smith C, Neau D, Guiguet M, Schwarze-Zander C, Moreno S, Guest JL, Monforte Ad, Tural C, Gill MJ, Bregenzer A, Kirk O, Saag M, Sterling TR, Crane HM, Sterne JA. Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration. J Acquir Immune Defic Syndr 2015;69:348-54. [PMID: 25848927 DOI: 10.1097/QAI.0000000000000603] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 4.1] [Reference Citation Analysis]
319 Horyniak D, Higgs P, Jenkinson R, Degenhardt L, Stoové M, Kerr T, Hickman M, Aitken C, Dietze P. Establishing the Melbourne Injecting Drug User Cohort Study (MIX): rationale, methods, and baseline and twelve-month follow-up results. Harm Reduct J 2013;10:11. [PMID: 23786848 DOI: 10.1186/1477-7517-10-11] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 6.8] [Reference Citation Analysis]
320 Mohamed Z, Rwegasha J, Kim JU, Shimakawa Y, Poiteau L, Chevaliez S, Bhagani S, Taylor-Robinson SD, Thursz MR, Mbwambo J, Lemoine M. The hepatitis C cascade of care in people who inject drugs in Dar es Salaam, Tanzania. J Viral Hepat 2018;25:1438-45. [PMID: 29974582 DOI: 10.1111/jvh.12966] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
321 Christensen S, Buggisch P, Mauss S, Böker KH, Müller T, Klinker H, Zimmermann T, Serfert Y, Weber B, Reimer J, Wedemeyer H; German Hepatitis C-Registry. Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapy-Data From the German Hepatitis C-Registry (DHC-R). Subst Abuse 2019;13:1178221819835847. [PMID: 30944519 DOI: 10.1177/1178221819835847] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
322 Kinson RM, Guo S, Wan YM, Manning V, Teoh HC, Wong KE. Burden of blood transmitted infections in substance users admitted for inpatient treatment in Singapore and the associated factors. Singapore Med J 2015;56:87-91. [PMID: 25588571 DOI: 10.11622/smedj.2014199] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
323 Kuo M, Janjua NZ, Burchell AN, Buxton JA, Krajden M, Gilbert M. Decreasing Hepatitis C Incidence Among a Population With Repeated Tests: British Columbia, Canada, 1993-2011. Am J Public Health 2015;105:1604-10. [PMID: 26066920 DOI: 10.2105/AJPH.2015.302591] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.9] [Reference Citation Analysis]
324 Stein MR, Soloway IJ, Jefferson KS, Roose RJ, Arnsten JH, Litwin AH. Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program. J Subst Abuse Treat. 2012;43:424-432. [PMID: 23036920 DOI: 10.1016/j.jsat.2012.08.007] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 5.1] [Reference Citation Analysis]
325 Büsch K, Hansson F, Holton M, Lagging M, Westin J, Kövamees J, Sällberg M, Söderholm J. Sick leave and disability pension in patients with chronic hepatitis C compared with a matched general population: a nationwide register study. BMJ Open 2020;10:e035996. [PMID: 32878754 DOI: 10.1136/bmjopen-2019-035996] [Reference Citation Analysis]
326 Wurcel AG, Anderson JE, Chui KK, Skinner S, Knox TA, Snydman DR, Stopka TJ. Increasing Infectious Endocarditis Admissions Among Young People Who Inject Drugs. Open Forum Infect Dis 2016;3:ofw157. [PMID: 27800528 DOI: 10.1093/ofid/ofw157] [Cited by in Crossref: 181] [Cited by in F6Publishing: 166] [Article Influence: 30.2] [Reference Citation Analysis]
327 Heimer R, Binka M, Koester S, Grund JC, Patel A, Paintsil E, Lindenbach BD. Recovery of Infectious Hepatitis C Virus From Injection Paraphernalia: Implications for Prevention Programs Serving People Who Inject Drugs. J Infect Dis 2018;217:466-73. [PMID: 28968665 DOI: 10.1093/infdis/jix427] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
328 Schwartz RP, Mitchell MM, O'Grady KE, Kelly SM, Gryczynski J, Mitchell SG, Gordon MS, Jaffe JH. Pharmacotherapy for opioid addiction in community corrections. Int Rev Psychiatry 2018;30:117-35. [PMID: 30522370 DOI: 10.1080/09540261.2018.1524373] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
329 Falade-Nwulia O, Ward KM, McCormick S, Mehta SH, Pitts SR, Katz S, Chander G, Thomas DL, Sulkowski M, Latkin CA. Network-based recruitment of people who inject drugs for hepatitis C testing and linkage to care. J Viral Hepat 2020;27:663-70. [PMID: 32045086 DOI: 10.1111/jvh.13274] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
330 Pradat P, Virlogeux V, Trépo E. Epidemiology and Elimination of HCV-Related Liver Disease. Viruses 2018;10:E545. [PMID: 30301201 DOI: 10.3390/v10100545] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
331 Tahamtan A, Tavakoli-Yaraki M, Mokhtari-Azad T, Teymoori-Rad M, Bont L, Shokri F, Salimi V. Opioids and Viral Infections: A Double-Edged Sword. Front Microbiol 2016;7:970. [PMID: 27446011 DOI: 10.3389/fmicb.2016.00970] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
332 Parry JV, Easterbrook P, Sands AR. One or two serological assay testing strategy for diagnosis of HBV and HCV infection? BMC Infect Dis. 2017;17:705. [PMID: 29143611 DOI: 10.1186/s12879-017-2774-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
333 Scott N, McBryde E, Vickerman P, Martin NK, Stone J, Drummer H, Hellard M. The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments. BMC Med 2015;13:198. [PMID: 26289050 DOI: 10.1186/s12916-015-0440-2] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 6.0] [Reference Citation Analysis]
334 Smith DJ, Jordan AE, Frank M, Hagan H. Spontaneous viral clearance of hepatitis C virus (HCV) infection among people who inject drugs (PWID) and HIV-positive men who have sex with men (HIV+ MSM): a systematic review and meta-analysis. BMC Infect Dis 2016;16:471. [PMID: 27595855 DOI: 10.1186/s12879-016-1807-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
335 Abadie R, Welch-Lazoritz M, Gelpi-Acosta C, Reyes JC, Dombrowski K. Understanding differences in HIV/HCV prevalence according to differentiated risk behaviors in a sample of PWID in rural Puerto Rico. Harm Reduct J 2016;13:10. [PMID: 26956029 DOI: 10.1186/s12954-016-0099-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
336 Norton BL, Akiyama MJ, Zamor PJ, Litwin AH. Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice. Infect Dis Clin North Am 2018;32:347-70. [PMID: 29778260 DOI: 10.1016/j.idc.2018.02.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
337 Bartholomew TS, Feaster DJ, Patel H, Forrest DW, Tookes HE. Reduction in injection risk behaviors after implementation of a syringe services program, Miami, Florida. J Subst Abuse Treat 2021;127:108344. [PMID: 34134863 DOI: 10.1016/j.jsat.2021.108344] [Reference Citation Analysis]
338 Perlman DC, Jordan AE, McKnight C, Young C, Delucchi KL, Sorensen JL, Des Jarlais DC, Masson CL. Viral hepatitis among drug users in methadone maintenance: associated factors, vaccination outcomes, and interventions. J Addict Dis 2014;33:322-31. [PMID: 25299236 DOI: 10.1080/10550887.2014.969623] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
339 Malekinejad M, Horvath H, Snyder H, Brindis CD. The discordance between evidence and health policy in the United States: the science of translational research and the critical role of diverse stakeholders. Health Res Policy Syst 2018;16:81. [PMID: 30115085 DOI: 10.1186/s12961-018-0336-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
340 Thakarar K, Weinstein ZM, Walley AY. Optimising health and safety of people who inject drugs during transition from acute to outpatient care: narrative review with clinical checklist. Postgrad Med J 2016;92:356-63. [PMID: 27004476 DOI: 10.1136/postgradmedj-2015-133720] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
341 Virlogeux V, Zoulim F, Pugliese P, Poizot-Martin I, Valantin MA, Cuzin L, Reynes J, Billaud E, Huleux T, Bani-Sadr F, Rey D, Frésard A, Jacomet C, Duvivier C, Cheret A, Hustache-Mathieu L, Hoen B, Cabié A, Cotte L; Dat’AIDS Study Group. Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination. BMC Med 2017;15:217. [PMID: 29249202 DOI: 10.1186/s12916-017-0979-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
342 Sanvisens A, Rivas I, Faure E, Espinach N, Hernandez-Rubio A, Majó X, Colom J, Muga R. Monitoring hepatitis C virus treatment rates in an Opioid Treatment Program: A longitudinal study. World J Gastroenterol 2020; 26(38): 5874-5883 [PMID: 33132641 DOI: 10.3748/wjg.v26.i38.5874] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
343 Mahmud S, Al Kanaani Z, Abu-Raddad LJ. Characterization of the hepatitis C virus epidemic in Pakistan. BMC Infect Dis 2019;19:809. [PMID: 31521121 DOI: 10.1186/s12879-019-4403-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
344 Sacks-Davis R, McBryde E, Grebely J, Hellard M, Vickerman P. Many hepatitis C reinfections that spontaneously clear may be undetected: Markov-chain Monte Carlo analysis of observational study data. J R Soc Interface 2015;12:20141197. [PMID: 25589564 DOI: 10.1098/rsif.2014.1197] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
345 Cunningham EB, Jacka B, DeBeck K, Applegate TL, Harrigan PR, Krajden M, Marshall BD, Montaner J, Lima VD, Olmstead AD, Milloy MJ, Wood E, Grebely J. Methamphetamine injecting is associated with phylogenetic clustering of hepatitis C virus infection among street-involved youth in Vancouver, Canada. Drug Alcohol Depend 2015;152:272-6. [PMID: 25977204 DOI: 10.1016/j.drugalcdep.2015.04.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
346 Tookey P, Mason K, Broad J, Behm M, Bondy L, Powis J. From client to co-worker: a case study of the transition to peer work within a multi-disciplinary hepatitis c treatment team in Toronto, Canada. Harm Reduct J 2018;15:41. [PMID: 30107808 DOI: 10.1186/s12954-018-0245-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
347 Proctor SL, Birch A, Herschman PL. Medication Treatment With Methadone or Buprenorphine: Differential Reasons for Premature Discharge. J Addict Med 2019;13:113-8. [PMID: 30199427 DOI: 10.1097/ADM.0000000000000456] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
348 Ross RS, Stambouli O, Grüner N, Marcus U, Cai W, Zhang W, Zimmermann R, Roggendorf M. Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots--performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification. Virol J. 2013;10:72. [PMID: 23497102 DOI: 10.1186/1743-422x-10-72] [Cited by in Crossref: 53] [Cited by in F6Publishing: 29] [Article Influence: 5.9] [Reference Citation Analysis]
349 Bluthenthal RN, Wenger L, Chu D, Quinn B, Thing J, Kral AH. Factors associated with initiating someone into illicit drug injection. Drug Alcohol Depend 2014;144:186-92. [PMID: 25282308 DOI: 10.1016/j.drugalcdep.2014.09.008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
350 Van Gerwen OT, Jani A, Long DM, Austin EL, Musgrove K, Muzny CA. Prevalence of Sexually Transmitted Infections and Human Immunodeficiency Virus in Transgender Persons: A Systematic Review. Transgend Health 2020;5:90-103. [PMID: 32656353 DOI: 10.1089/trgh.2019.0053] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
351 Faryar KA, Ancona RM, Reau Z, Lyss SB, Braun RS, Rademaker T, Sickles RK, Lyons MS. HIV detection by an emergency department HIV screening program during a regional outbreak among people who inject drugs. PLoS One 2021;16:e0251756. [PMID: 34003855 DOI: 10.1371/journal.pone.0251756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
352 Esmaeili A, Mirzazadeh A, Carter GM, Esmaeili A, Hajarizadeh B, Sacks HS, Page KA. Higher incidence of HCV in females compared to males who inject drugs: A systematic review and meta-analysis. J Viral Hepat 2017;24:117-27. [PMID: 27790803 DOI: 10.1111/jvh.12628] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
353 Bluthenthal RN, Wenger L, Chu D, Lorvick J, Quinn B, Thing JP, Kral AH. Factors associated with being asked to initiate someone into injection drug use. Drug Alcohol Depend 2015;149:252-8. [PMID: 25735468 DOI: 10.1016/j.drugalcdep.2015.02.011] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
354 Maistat L, Kravchenko N, Reddy A. Hepatitis C in Eastern Europe and Central Asia: a survey of epidemiology, treatment access and civil society activity in eleven countries. Hepatol Med Policy 2017;2:9. [PMID: 30288322 DOI: 10.1186/s41124-017-0026-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
355 Al Wahaibi N, Al Lawati A, Al Ruqeishy F, Al Khatri A, Al-Farsi Y, Juma TMA, Al Hinai F, Al-Sibani N, Mahadevan S, Al-Adawi S. The characteristics and patterns of utilization of healthcare services among Omanis with substance use disorders attending therapy for cessation. PLoS One 2019;14:e0210532. [PMID: 30703131 DOI: 10.1371/journal.pone.0210532] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
356 Dong R, Yang H, Li J, Wang R, Wang L, Li Y. Giant Spider Angioma Following Cirrhosis in HIV-Infected Individuals. The American Journal of the Medical Sciences 2022. [DOI: 10.1016/j.amjms.2021.12.007] [Reference Citation Analysis]
357 Jacka B, Applegate T, Poon AF, Raghwani J, Harrigan PR, DeBeck K, Milloy MJ, Krajden M, Olmstead A, Joy JB, Marshall BD, Hayashi K, Pybus OG, Lima VD, Magiorkinis G, Montaner J, Lamoury F, Dore GJ, Wood E, Grebely J. Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada. J Hepatol 2016;64:1247-55. [PMID: 26924451 DOI: 10.1016/j.jhep.2016.02.031] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
358 Wade AJ, Doyle JS, Gane E, Stedman C, Draper B, Iser D, Roberts SK, Kemp W, Petrie D, Scott N, Higgs P, Agius PA, Roney J, Stothers L, Thompson AJ, Hellard ME. Community-based provision of direct-acting antiviral therapy for hepatitis C: study protocol and challenges of a randomized controlled trial. Trials 2018;19:383. [PMID: 30012192 DOI: 10.1186/s13063-018-2768-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
359 Ramezani A, Amirmoezi R, Volk JE, Aghakhani A, Zarinfar N, McFarland W, Banifazl M, Mostafavi E, Eslamifar A, Sofian M. HCV, HBV, and HIV seroprevalence, coinfections, and related behaviors among male injection drug users in Arak, Iran. AIDS Care 2014;26:1122-6. [PMID: 24499303 DOI: 10.1080/09540121.2014.882485] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
360 Nadol P, O'connor S, Duong H, Le LV, Thang PH, Tram TH, Ha HT, Mcconnell MS, Partridge J, Kaldor J, Law M, Nguyen TA. Findings from integrated behavioral and biologic survey among males who inject drugs (MWID) - Vietnam, 2009-2010: evidence of the need for an integrated response to HIV, hepatitis B virus, and hepatitis C virus. PLoS One 2015;10:e0118304. [PMID: 25692469 DOI: 10.1371/journal.pone.0118304] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
361 Ramers CB, Trooskin SB. Hepatitis C Virus in the Modern Direct-Acting Antiviral Era: Where Have All the Special Populations Gone? Clin Liver Dis (Hoboken) 2018;12:143-9. [PMID: 30988932 DOI: 10.1002/cld.786] [Reference Citation Analysis]
362 Hall N, Le L, Majmudar I, Teesson M, Mihalopoulos C. Treatment-seeking behaviour among people with opioid use disorder in the high-income countries: A systematic review and meta-analysis. PLoS One 2021;16:e0258620. [PMID: 34653220 DOI: 10.1371/journal.pone.0258620] [Reference Citation Analysis]
363 Ramia S, Melhem NM, Kreidieh K. Hepatitis C virus infection in the Middle East and North Africa “MENA” region: injecting drug users (IDUs) is an under-investigated population. Infection. 2012;40:1-10. [PMID: 22237470 DOI: 10.1007/s15010-011-0236-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
364 Jefferies M, Rauff B, Rashid H, Lam T, Rafiq S. Update on global epidemiology of viral hepatitis and preventive strategies. World J Clin Cases 2018; 6(13): 589-599 [PMID: 30430114 DOI: 10.12998/wjcc.v6.i13.589] [Cited by in CrossRef: 95] [Cited by in F6Publishing: 71] [Article Influence: 23.8] [Reference Citation Analysis]
365 Crowley D, Murtagh R, Cullen W, Lambert JS, McHugh T, Van Hout MC. Hepatitis C virus infection in Irish drug users and prisoners - a scoping review. BMC Infect Dis 2019;19:702. [PMID: 31395032 DOI: 10.1186/s12879-019-4218-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
366 Gutkind S, Schackman BR, Morgan JR, Leff JA, Agyemang L, Murphy SM, Akiyama MJ, Norton BL, Litwin AH, Linas BP. Cost-effectiveness of Hepatitis C Virus Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs. Clin Infect Dis 2020;70:1397-405. [PMID: 31095683 DOI: 10.1093/cid/ciz384] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
367 Karimi SE, Bayani A, Higgs P, Bayat AH, Hemmat M, Ahounbar E, Armoon B, Fakhri Y. Prevalence and high risk behaviours associated with HCV testing among people who inject drugs: a systematic review and Meta-analysis. Subst Abuse Treat Prev Policy 2020;15:64. [PMID: 32831107 DOI: 10.1186/s13011-020-00306-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
368 Falade-Nwulia O, Irvin R, Merkow A, Sulkowski M, Niculescu A, Olsen Y, Stoller K, Thomas DL, Latkin C, Mehta SH. Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore. J Subst Abuse Treat 2019;100:45-51. [PMID: 30898327 DOI: 10.1016/j.jsat.2019.01.021] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
369 Bergenstrom A, Achakzai B, Furqan S, ul Haq M, Khan R, Saba M. Drug-related HIV epidemic in Pakistan: a review of current situation and response and the way forward beyond 2015. Harm Reduct J 2015;12:43. [PMID: 26471874 DOI: 10.1186/s12954-015-0079-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
370 Azbel L, Wickersham JA, Grishaev Y, Dvoryak S, Altice FL. Burden of infectious diseases, substance use disorders, and mental illness among Ukrainian prisoners transitioning to the community. PLoS One. 2013;8:e59643. [PMID: 23527238 DOI: 10.1371/journal.pone.0059643] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 5.7] [Reference Citation Analysis]
371 Rich ZC, Chu C, Mao J, Zhou K, Cai W, Ma Q, Volberding P, Tucker JD. Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals. BMC Public Health 2016;16:994. [PMID: 27645935 DOI: 10.1186/s12889-016-3671-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
372 El Ibrahimi S, Hallvik S, Johnston K, Leichtling G, Korthuis PT, Chan B, Hartung DM. Characteristics and health care events of patients admitted to treatment for both heroin and methamphetamine compared to patients admitted for heroin only. J Subst Abuse Treat 2022;132:108615. [PMID: 34600772 DOI: 10.1016/j.jsat.2021.108615] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
373 Boyd A, Duchesne L, Lacombe K. Research gaps in viral hepatitis. J Int AIDS Soc 2018;21 Suppl 2:e25054. [PMID: 29633564 DOI: 10.1002/jia2.25054] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
374 White SR, Hutchinson SJ, Taylor A, Bird SM. Modeling the initiation of others into injection drug use, using data from 2,500 injectors surveyed in Scotland during 2008-2009. Am J Epidemiol 2015;181:771-80. [PMID: 25787265 DOI: 10.1093/aje/kwu345] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
375 Mittal ML, Beletsky L, Patiño E, Abramovitz D, Rocha T, Arredondo J, Bañuelos A, Rangel G, Strathdee SA. Prevalence and correlates of needle-stick injuries among active duty police officers in Tijuana, Mexico. J Int AIDS Soc 2016;19:20874. [PMID: 27435711 DOI: 10.7448/IAS.19.4.20874] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
376 Jung YJ, Albrecht JA, Kwak JW, Park JW. Direct quantitative analysis of HCV RNA by atomic force microscopy without labeling or amplification. Nucleic Acids Res 2012;40:11728-36. [PMID: 23074195 DOI: 10.1093/nar/gks953] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
377 Coutinho C, Bastos LS, da Mota JC, Toledo L, Costa K, Bertoni N, Bastos FI. The risks of HCV infection among Brazilian crack cocaine users: incorporating diagnostic test uncertainty. Sci Rep 2019;9:443. [PMID: 30679480 DOI: 10.1038/s41598-018-35657-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
378 Scott N, Hellard M, McBryde ES. Modeling hepatitis C virus transmission among people who inject drugs: Assumptions, limitations and future challenges. Virulence 2016;7:201-8. [PMID: 26305706 DOI: 10.1080/21505594.2015.1085151] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
379 van Santen DK, de Vos AS, Matser A, Willemse SB, Lindenburg K, Kretzschmar ME, Prins M, de Wit GA. Cost-Effectiveness of Hepatitis C Treatment for People Who Inject Drugs and the Impact of the Type of Epidemic; Extrapolating from Amsterdam, the Netherlands. PLoS One 2016;11:e0163488. [PMID: 27711200 DOI: 10.1371/journal.pone.0163488] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
380 Hu Y, Yu C, Chen B, Wang L. Implication of reported viral hepatitis incidence rate change in Hubei Province, China, between 2004-2010. J Huazhong Univ Sci Technolog Med Sci 2012;32:428-33. [PMID: 22684570 DOI: 10.1007/s11596-012-0074-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
381 Hamoudi W, Ali SA, Abdallat M, Estes CR, Razavi HA. HCV infection prevalence in a population recruited at health centers in Jordan. J Epidemiol Glob Health 2013;3:67-71. [PMID: 23856567 DOI: 10.1016/j.jegh.2013.02.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
382 Azevedo TC, Zwahlen M, Rauch A, Egger M, Wandeler G. Hepatitis C in HIV-infected individuals: a systematic review and meta-analysis of estimated prevalence in Africa. J Int AIDS Soc. 2016;19:20711. [PMID: 27293220 DOI: 10.7448/ias.19.1.20711] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
383 Abdel Allah HMM, Zahran WE, El-Masry SA, El-Bendary M, Soliman AF. Association of MTHFR and TYMS gene polymorphisms with the susceptibility to HCC in Egyptian HCV cirrhotic patients. Clin Exp Med 2021. [PMID: 34297238 DOI: 10.1007/s10238-021-00747-3] [Reference Citation Analysis]
384 Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, Stone J, Cunningham EB, Trickey A, Dumchev K, Lynskey M, Griffiths P, Mattick RP, Hickman M, Larney S. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5:e1192-e1207. [PMID: 29074409 DOI: 10.1016/s2214-109x(17)30375-3] [Cited by in Crossref: 539] [Cited by in F6Publishing: 287] [Article Influence: 107.8] [Reference Citation Analysis]
385 Huik K, Avi R, Pauskar M, Kallas E, Jõgeda EL, Karki T, Marsh K, Des Jarlais D, Uusküla A, Lutsar I. Association between TLR3 rs3775291 and resistance to HIV among highly exposed Caucasian intravenous drug users. Infect Genet Evol 2013;20:78-82. [PMID: 23962581 DOI: 10.1016/j.meegid.2013.08.008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
386 Garimella T, Wang R, Luo WL, Wastall P, Kandoussi H, DeMicco M, Bruce RD, Hwang C, Bertz R, Bifano M. Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone. Antimicrob Agents Chemother 2015;59:5503-10. [PMID: 26124175 DOI: 10.1128/AAC.00478-15] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
387 Keten D, Emin Ova M, Sirri Keten H, Keten A, Gulderen E, Tumer S, Caliskan A, Kulotu S. The Prevalence of Hepatitis B and C Among Prisoners in Kahramanmaras, Turkey. Jundishapur J Microbiol 2016;9:e31598. [PMID: 27127594 DOI: 10.5812/jjm.31598] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
388 Fraser H, Martin NK, Brummer-Korvenkontio H, Carrieri P, Dalgard O, Dillon J, Goldberg D, Hutchinson S, Jauffret-Roustide M, Kåberg M, Matser AA, Matičič M, Midgard H, Mravcik V, Øvrehus A, Prins M, Reimer J, Robaeys G, Schulte B, van Santen DK, Zimmermann R, Vickerman P, Hickman M. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. J Hepatol 2018;68:402-11. [PMID: 29080808 DOI: 10.1016/j.jhep.2017.10.010] [Cited by in Crossref: 72] [Cited by in F6Publishing: 62] [Article Influence: 18.0] [Reference Citation Analysis]
389 Wu ZQ, Tan L, Gan WQ, Mo ZS, Chen DB, Wang PP, Zhao QY, Xie DY, Gao ZL. The relationship between the clearance of HBsAg and the remodeling of B cell subsets in CHB patients treated with Peg-IFN-α. Ann Transl Med 2021;9:414. [PMID: 33842635 DOI: 10.21037/atm-21-409] [Reference Citation Analysis]
390 Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, Taylor LE, Dore GJ. Recomendaciones para el manejo de la infección por el virus de la hepatitis C entre usuarios de drogas por vía parenteral. International Journal of Drug Policy 2015. [DOI: 10.1016/j.drugpo.2015.11.011] [Reference Citation Analysis]
391 Ajonijebu DC, Abboussi O, Russell VA, Mabandla MV, Daniels WMU. Epigenetics: a link between addiction and social environment. Cell Mol Life Sci 2017;74:2735-47. [PMID: 28255755 DOI: 10.1007/s00018-017-2493-1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
392 Miao Z, Zhang S, Ou X, Li S, Ma Z, Wang W, Peppelenbosch MP, Liu J, Pan Q. Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection. J Infect Dis. 2020;221:1677-1687. [PMID: 31778167 DOI: 10.1093/infdis/jiz633] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 39.0] [Reference Citation Analysis]
393 Roux P, Sagaon-Teyssier L, Lions C, Fugon L, Verger P, Carrieri MP. HCV seropositivity in inmates and in the general population: an averaging approach to establish priority prevention interventions. BMJ Open. 2014;4:e005694. [PMID: 25331969 DOI: 10.1136/bmjopen-2014-005694] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
394 Mantzoukis K, Rodríguez-Perálvarez M, Buzzetti E, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Pharmacological interventions for acute hepatitis B infection: an attempted network meta-analysis. Cochrane Database Syst Rev 2017;3:CD011645. [PMID: 28321877 DOI: 10.1002/14651858.CD011645.pub2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
395 Crowley D, Van Hout MC, Murphy C, Kelly E, Lambert JS, Cullen W. Hepatitis C virus screening and treatment in Irish prisons from a governor and prison officer perspective - a qualitative exploration. Health Justice 2018;6:23. [PMID: 30569249 DOI: 10.1186/s40352-018-0081-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
396 Wiktor SZ. Viral Hepatitis. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Disease Control Priorities, Third Edition (Volume 6): Major Infectious Diseases. The World Bank; 2017. pp. 401-9. [DOI: 10.1596/978-1-4648-0524-0_ch16] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
397 Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J 2013;10:7. [PMID: 23651646 DOI: 10.1186/1477-7517-10-7] [Cited by in Crossref: 147] [Cited by in F6Publishing: 145] [Article Influence: 16.3] [Reference Citation Analysis]
398 Martin NK, Vickerman P, Dore GJ, Hickman M. The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention. Curr Opin HIV AIDS. 2015;10:374-380. [PMID: 26248124 DOI: 10.1097/coh.0000000000000179] [Cited by in Crossref: 97] [Cited by in F6Publishing: 54] [Article Influence: 16.2] [Reference Citation Analysis]
399 Voon P, Callon C, Nguyen P, Dobrer S, Montaner J, Wood E, Kerr T. Self-management of pain among people who inject drugs in Vancouver. Pain Manag 2014;4:27-35. [PMID: 24641341 DOI: 10.2217/pmt.13.62] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
400 Eddie D, Greene MC, White WL, Kelly JF. Medical Burden of Disease Among Individuals in Recovery From Alcohol and Other Drug Problems in the United States: Findings From the National Recovery Survey. J Addict Med 2019;13:385-95. [PMID: 31589181 DOI: 10.1097/ADM.0000000000000512] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
401 Truong L, Tat J, Booy M, Le A, Marasigan JM, Yuan C, Zeng A, Panchal A, Sadler GR. The Asian Grocery Store-Based Cancer Education Program: Creating New Education Modules. J Cancer Educ 2016;31:292-300. [PMID: 25971431 DOI: 10.1007/s13187-015-0836-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
402 Stone J, Martin NK, Hickman M, Hutchinson SJ, Aspinall E, Taylor A, Munro A, Dunleavy K, Peters E, Bramley P, Hayes PC, Goldberg DJ, Vickerman P. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. Addiction 2017;112:1302-14. [PMID: 28257600 DOI: 10.1111/add.13783] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 12.0] [Reference Citation Analysis]
403 Feng HP, Guo Z, Caro L, Marshall WL, Liu F, Panebianco D, Vaddady P, Barbour A, Reitmann C, Jumes P, Gilmartin J, Wolford D, Valesky R, Martinho M, Butterton JR, Iwamoto M, Fraser I, Webster L, Yeh WW. No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Buprenorphine/Naloxone in Healthy Participants and Participants Receiving Stable Opioid Agonist Therapy. Clin Transl Sci 2018;11:562-72. [PMID: 30040871 DOI: 10.1111/cts.12565] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
404 Kouroumalis E, Voumvouraki A. Hepatitis C virus: A critical approach to who really needs treatment. World J Hepatol 2022; 14(1): 1-44 [DOI: 10.4254/wjh.v14.i1.1] [Reference Citation Analysis]
405 Hayashi K, Milloy MJ, Wood E, Dong H, Montaner JS, Kerr T. Predictors of liver-related death among people who inject drugs in Vancouver, Canada: a 15-year prospective cohort study. J Int AIDS Soc 2014;17:19296. [PMID: 25391765 DOI: 10.7448/IAS.17.1.19296] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
406 Midgard H, Bramness JG, Skurtveit S, Haukeland JW, Dalgard O. Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study. PLoS One 2016;11:e0166451. [PMID: 27846264 DOI: 10.1371/journal.pone.0166451] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
407 Zeremski M, Dimova RB, Zavala R, Kritz S, Lin M, Smith BD, Zibbell JE, Talal AH. Hepatitis C virus-related knowledge and willingness to receive treatment among patients on methadone maintenance. J Addict Med. 2014;8:249-257. [PMID: 24820257 DOI: 10.1097/adm.0000000000000041] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
408 Pfaender S, von Hahn T, Steinmann J, Ciesek S, Steinmann E. Prevention strategies for blood-borne viruses-in the Era of vaccines, direct acting antivirals and antiretroviral therapy. Rev Med Virol 2016;26:330-9. [PMID: 27185010 DOI: 10.1002/rmv.1890] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
409 Bruggmann P, Litwin AH. Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. Clin Infect Dis. 2013;57 Suppl 2:S56-S61. [PMID: 23884067 DOI: 10.1093/cid/cit271] [Cited by in Crossref: 137] [Cited by in F6Publishing: 131] [Article Influence: 17.1] [Reference Citation Analysis]
410 Prouté M, Le Coeur S, Tiv MH, Dub T, Jongpaijitsakul P, Ratnamhin A, Angkurawaranon C, Aramrattana A, Lallemant M. Risky injection practices and HCV awareness in Chiang Mai Province, Thailand: a respondent-driven sampling study of people who inject drugs. BMC Public Health 2020;20:1450. [PMID: 32972359 DOI: 10.1186/s12889-020-09549-w] [Reference Citation Analysis]
411 Tsui JI, Mirzazadeh A, Hahn JA, Maher L, Bruneau J, Grebely J, Hellard M, Kim AY, Shoukry NH, Cox AL, Prins M, Dore GJ, Lauer G, Lloyd AR, Page K. The effects of alcohol on spontaneous clearance of acute hepatitis C virus infection in females versus males. Drug Alcohol Depend 2016;169:156-62. [PMID: 27816863 DOI: 10.1016/j.drugalcdep.2016.10.024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
412 Perlman DC, Jordan AE, Uuskula A, Huong DT, Masson CL, Schackman BR, Des Jarlais DC. An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential. Int J Drug Policy. 2015;26:1056-1063. [PMID: 26050614 DOI: 10.1016/j.drugpo.2015.04.015] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
413 Siddharta A, Pfaender S, Malassa A, Doerrbecker J, Anggakusuma, Engelmann M, Nugraha B, Steinmann J, Todt D, Vondran FW, Mateu-Gelabert P, Goffinet C, Steinmann E. Inactivation of HCV and HIV by microwave: a novel approach for prevention of virus transmission among people who inject drugs. Sci Rep 2016;6:36619. [PMID: 27857152 DOI: 10.1038/srep36619] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
414 Ruta S, Cernescu C. Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes. World J Gastroenterol 2015; 21(38): 10811-10823 [PMID: 26478672 DOI: 10.3748/wjg.v21.i38.10811] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
415 Chang MH, Moonesinghe R, Schieber LZ, Truman BI. Opioid-Related Diagnoses and Concurrent Claims for HIV, HBV, or HCV among Medicare Beneficiaries, United States, 2015. J Clin Med 2019;8:E1768. [PMID: 31652928 DOI: 10.3390/jcm8111768] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
416 Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, Foster GR, Dillon JF, Goldberg DJ, Dore GJ, Hickman M. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013;58:1598-609. [PMID: 23553643 DOI: 10.1002/hep.26431] [Cited by in Crossref: 368] [Cited by in F6Publishing: 349] [Article Influence: 40.9] [Reference Citation Analysis]
417 Shand FL, Day C, Rawlinson W, Degenhardt L, Martin NG, Nelson EC. Hepatitis C testing and status among opioid substitution treatment clients in New South Wales. Aust N Z J Public Health 2014;38:160-4. [PMID: 24690055 DOI: 10.1111/1753-6405.12173] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
418 Tsui JI, Burt R, Thiede H, Glick SN. Utilization of buprenorphine and methadone among opioid users who inject drugs. Subst Abus 2018;39:83-8. [PMID: 28796591 DOI: 10.1080/08897077.2017.1363844] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
419 Meyer JP, Moghimi Y, Marcus R, Lim JK, Litwin AH, Altice FL. Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum. Int J Drug Policy 2015;26:922-35. [PMID: 26077144 DOI: 10.1016/j.drugpo.2015.05.002] [Cited by in Crossref: 79] [Cited by in F6Publishing: 71] [Article Influence: 11.3] [Reference Citation Analysis]
420 Neaigus A, Reilly KH, Jenness SM, Hagan H, Wendel T, Gelpi-Acosta C, Marshall DM 4th. Trends in HIV and HCV Risk Behaviors and Prevalent Infection Among People Who Inject Drugs in New York City, 2005-2012. J Acquir Immune Defic Syndr 2017;75 Suppl 3:S325-32. [PMID: 28604434 DOI: 10.1097/QAI.0000000000001407] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
421 Zimmermann R, Marcus U, Schäffer D, Leicht A, Wenz B, Nielsen S, Santos-Hövener C, Ross RS, Stambouli O, Ratsch BA, Bannert N, Bock CT, Kücherer C, Hamouda O. A multicentre sero-behavioural survey for hepatitis B and C, HIV and HTLV among people who inject drugs in Germany using respondent driven sampling. BMC Public Health 2014;14:845. [PMID: 25124485 DOI: 10.1186/1471-2458-14-845] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
422 Litwin AH, Soloway IJ, Cockerham-Colas L, Reynoso S, Heo M, Tenore C, Roose RJ. Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program. Int J Drug Policy 2015;26:1014-9. [PMID: 26341685 DOI: 10.1016/j.drugpo.2015.08.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
423 Kalantari H, Karimzadeh H, Kalantari S, Talebi M, Yaran M, Golpayegani J. Correlation between Vitamin D3 level and extrahepatic manifestation in chronic hepatitis type-C virus patients. J Res Med Sci 2018;23:22. [PMID: 29692819 DOI: 10.4103/jrms.JRMS_366_17] [Reference Citation Analysis]
424 Leprêtre A, Ba I, Lacombe K, Maynart M, Toufik A, Ndiaye O, Kane CT, Gozlan J, Tine J, Ndoye I, Raguin G, Girard PM. Prevalence and behavioural risks for HIV and HCV infections in a population of drug users of Dakar, Senegal: the ANRS 12243 UDSEN study. J Int AIDS Soc 2015;18:19888. [PMID: 26004637 DOI: 10.7448/IAS.18.1.19888] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 3.1] [Reference Citation Analysis]
425 El-Bassel N, Gilbert L, Terlikbayeva A, Wu E, Beyrer C, Shaw S, Hunt T, Ma X, Chang M, Ismayilova L, Tukeyev M, Zhussupov B, Rozental Y. HIV among injection drug users and their intimate partners in Almaty, Kazakhstan. AIDS Behav 2013;17:2490-500. [PMID: 23612942 DOI: 10.1007/s10461-013-0484-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
426 Asrani SK, Davis GL. Impact of birth cohort screening for hepatitis C. Curr Gastroenterol Rep 2014;16:381. [PMID: 24595618 DOI: 10.1007/s11894-014-0381-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
427 Rosińska M, Sierosławski J, Wiessing L. High regional variability of HIV, HCV and injecting risks among people who inject drugs in Poland: comparing a cross-sectional bio-behavioural study with case-based surveillance. BMC Infect Dis 2015;15:83. [PMID: 25879904 DOI: 10.1186/s12879-015-0828-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
428 Page K, Morris MD, Hahn JA, Maher L, Prins M. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis 2013;57 Suppl 2:S32-8. [PMID: 23884063 DOI: 10.1093/cid/cit300] [Cited by in Crossref: 114] [Cited by in F6Publishing: 116] [Article Influence: 14.3] [Reference Citation Analysis]
429 Jiang R, Lee I, Lee TA, Pickard AS. The societal cost of heroin use disorder in the United States. PLoS One 2017;12:e0177323. [PMID: 28557994 DOI: 10.1371/journal.pone.0177323] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
430 Larios SE, Masson CL, Shopshire MS, Hettema J, Jordan AE, McKnight C, Young C, Khalili M, Seewald RM, Min A, Hengl N, Sorensen JL, Des Jarlais DC, Perlman DC. Education and counseling in the methadone treatment setting improves knowledge of viral hepatitis. J Subst Abuse Treat 2014;46:528-31. [PMID: 24462241 DOI: 10.1016/j.jsat.2013.10.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
431 Hahné SJ, Veldhuijzen IK, Wiessing L, Lim TA, Salminen M, Laar Mv. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis. 2013;13:181. [PMID: 23597411 DOI: 10.1186/1471-2334-13-181] [Cited by in Crossref: 142] [Cited by in F6Publishing: 136] [Article Influence: 15.8] [Reference Citation Analysis]
432 Javanbakht M, Mirahmadizadeh A, Mashayekhi A. The long-term effectiveness of methadone maintenance treatment in prevention of hepatitis C virus among illicit drug users: a modeling study. Iran Red Crescent Med J 2014;16:e13484. [PMID: 24719731 DOI: 10.5812/ircmj.13484] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
433 Larney S, Kopinski H, Beckwith CG, Zaller ND, Jarlais DD, Hagan H, Rich JD, van den Bergh BJ, Degenhardt L. Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatology 2013;58:1215-24. [PMID: 23504650 DOI: 10.1002/hep.26387] [Cited by in Crossref: 192] [Cited by in F6Publishing: 185] [Article Influence: 21.3] [Reference Citation Analysis]
434 Nolan S, Dias Lima V, Fairbairn N, Kerr T, Montaner J, Grebely J, Wood E. The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. Addiction 2014;109:2053-9. [PMID: 25041346 DOI: 10.1111/add.12682] [Cited by in Crossref: 95] [Cited by in F6Publishing: 91] [Article Influence: 11.9] [Reference Citation Analysis]
435 Petrovic J, Salkic N, Piljic D, Ahmetagic S, Jahic R, Porobic H, Smriko-Nuhanovic A, Hasanovic M. Clinical Characteristics and Treatment Efficasy of Chronic HCV Infection Among Intravenous Drug Users in Tuzla Canton. Mater Sociomed 2018;30:276-81. [PMID: 30936792 DOI: 10.5455/msm.2018.30.276-281] [Reference Citation Analysis]
436 Shaheen MA, Idrees M. Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease. World J Hepatol 2015; 7(3): 616-627 [PMID: 25848486 DOI: 10.4254/wjh.v7.i3.616] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
437 Ng KT, Lee YM, Al-Darraji HA, Xia X, Takebe Y, Chan KG, Lu L, Mahadeva S, Kamarulzaman A, Tee KK. Genome sequence of the hepatitis C virus subtype 6n isolated from malaysia. Genome Announc. 2013;1:pii: e00168-12. [PMID: 23409272 DOI: 10.1128/genomea.00168-12] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
438 Alavian SM, Mirahmadizadeh A, Javanbakht M, Keshtkaran A, Heidari A, Mashayekhi A, Salimi S, Hadian M. Effectiveness of Methadone Maintenance Treatment in Prevention of Hepatitis C Virus Transmission among Injecting Drug Users. Hepat Mon 2013;13:e12411. [PMID: 24069039 DOI: 10.5812/hepatmon.12411] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
439 Khorami F, Sobhani SA, Davoudian P, Khajeh E. Prevalence of HBc-Ab among HBs-Ag negative healthy blood donors in south of Iran. Electron Physician 2013;5:659-63. [PMID: 26120400 DOI: 10.14661/2013.659-663] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
440 Doerrbecker J, Behrendt P, Mateu-Gelabert P, Ciesek S, Riebesehl N, Wilhelm C, Steinmann J, Pietschmann T, Steinmann E. Transmission of hepatitis C virus among people who inject drugs: viral stability and association with drug preparation equipment. J Infect Dis 2013;207:281-7. [PMID: 23129759 DOI: 10.1093/infdis/jis677] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 4.8] [Reference Citation Analysis]
441 Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis 2012;31:207-25. [PMID: 22873183 DOI: 10.1080/10550887.2012.694598] [Cited by in Crossref: 239] [Cited by in F6Publishing: 184] [Article Influence: 23.9] [Reference Citation Analysis]
442 Bankwitz D, Krey T, Pietschmann T. [Development approaches for vaccines against hepatitis C virus infections]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2022. [PMID: 35015104 DOI: 10.1007/s00103-021-03477-9] [Reference Citation Analysis]
443 Rossi C, Shrier I, Marshall L, Cnossen S, Schwartzman K, Klein MB, Schwarzer G, Greenaway C. Seroprevalence of chronic hepatitis B virus infection and prior immunity in immigrants and refugees: a systematic review and meta-analysis. PLoS One. 2012;7:e44611. [PMID: 22957088 DOI: 10.1371/journal.pone.0044611] [Cited by in Crossref: 84] [Cited by in F6Publishing: 80] [Article Influence: 8.4] [Reference Citation Analysis]
444 Sekiba K, Otsuka M, Ohno M, Yamagami M, Kishikawa T, Suzuki T, Ishibashi R, Seimiya T, Tanaka E, Koike K. Hepatitis B virus pathogenesis: Fresh insights into hepatitis B virus RNA. World J Gastroenterol 2018; 24(21): 2261-2268 [PMID: 29881235 DOI: 10.3748/wjg.v24.i21.2261] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
445 Lazarus JV, Mozalevskis A, Safreed-Harmon K, Eramova I. Strengthening hepatitis B and C surveillance in Europe: results from the two global hepatitis policy surveys (2013 and 2014). Hepatol Med Policy 2016;1:3. [PMID: 30288307 DOI: 10.1186/s41124-016-0009-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
446 Do A, Reau NS. Chronic Viral Hepatitis: Current Management and Future Directions. Hepatol Commun 2020;4:329-41. [PMID: 32140652 DOI: 10.1002/hep4.1480] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
447 Chaabna K, Cheema S, Abraham A, Alrouh H, Lowenfels AB, Maisonneuve P, Mamtani R. Systematic overview of hepatitis C infection in the Middle East and North Africa. World J Gastroenterol 2018; 24(27): 3038-3054 [PMID: 30038471 DOI: 10.3748/wjg.v24.i27.3038] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
448 Smith DJ, Neurer J, Jordan AE, Hagan H. Epidemiology of Hepatitis C Virus Among People Who Inject Drugs: Protocol for a Systematic Review and Meta-Analysis. JMIR Res Protoc 2017;6:e201. [PMID: 29054830 DOI: 10.2196/resprot.7936] [Reference Citation Analysis]
449 Daw MA, El-Bouzedi A, Ahmed MO, Dau AA, Agnan MM. Hepatitis C Virus in North Africa: An Emerging Threat. ScientificWorldJournal 2016;2016:7370524. [PMID: 27610403 DOI: 10.1155/2016/7370524] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
450 Mahmud S, Mumtaz GR, Chemaitelly H, Al Kanaani Z, Kouyoumjian SP, Hermez JG, Abu-Raddad LJ. The status of hepatitis C virus infection among people who inject drugs in the Middle East and North Africa. Addiction 2020;115:1244-62. [PMID: 32009283 DOI: 10.1111/add.14944] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
451 Jordan AE, Masson CL, Mateu-Gelabert P, McKnight C, Pepper N, Bouche K, Guzman L, Kletter E, Seewald RM, Des-Jarlais DC. Perceptions of drug users regarding hepatitis C screening and care: a qualitative study. Harm Reduct J. 2013;10:10. [PMID: 23786800 DOI: 10.1186/1477-7517-10-10] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
452 Scott N, Wilson DP, Thompson AJ, Barnes E, El-Sayed M, Benzaken AS, Drummer HE, Hellard ME. The case for a universal hepatitis C vaccine to achieve hepatitis C elimination. BMC Med 2019;17:175. [PMID: 31530275 DOI: 10.1186/s12916-019-1411-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]